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ABSTRACT
Psychosocial distress, characterized by increased perceived stress, anxiety and
mood disturbance, is a common response of women to a diagnosis of breast cancer
(Northouse, 1992; Pettingale et al., 1988; Stark and House, 2000; Witek-Janusek et al.,
2007). This psychosocial distress leads to activation of the hypothalamic-pituitaryadrenocortical (HPA) axis and increased circulating glucocorticoids (GCs) (Chrousos,
2000; Chrousos and Gold, 1992; Schoneveld and Cidlowski, 2007). Increased
psychosocial distress and increased HPA activation can lead to immune dysregulation
consisting of reduced natural killer (NK) cell activity (NKCA) (Biondi, 2001; KiecoltGlaser et al., 1987; Kiecolt-Glaser et al., 2002; Witek-Janusek et al., 2008; WitekJanusek et al., 2007). This is of particular relevance to women with breast cancer as
altered immune cell function is important for tumor control (Curcio et al., 2003; D'Anello
et al., 2010; Diefenbach and Raulet, 2002; Hartman et al., 2011; Kishimoto, 2005;
Knupfer and Preiss, 2007; Street et al., 2001; van den Broek et al., 1996). The
psychological distress in response to a diagnosis of breast cancer diagnosis has relevance
for women with breast cancer, as it may contribute to poor cancer outcome.
Yet little is known about the molecular mechanism(s) by which psychosocial distress
results in NK cell dysregulation. The overall purpose of this project was to evaluate a
potential mechanism posited to underlie altered NK cell function observed in women
with breast cancer. Increased psychosocial distress increases GCs like cortisol which can
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impact NK cell function; therefore cortisol levels were measured. Morning cortisol rise
inversely correlated with NKCA, such that women with decreased NKCA exhibited an
elevation in the morning cortisol rise. Additionally, in vitro treatment of a human NK
cell line, NK92 cells, treated with a synthetic GC (dexamethasone) resulted in decreased
NKCA. Together these results suggest that cortisol altered lytic function of NK cells. As
GCs have been shown to alter cell function by altering epigenetic patterns, global histone
modifications were investigated. In both ex vivo analysis of NK cells derived from
peripheral blood of women with breast cancer and NK92 cells treated with GCs
significant reductions in global acetylation of histone 4 lysine 8 (H4-K8-Ac) were
observed, when compared to the age-matched Control women or untreated NK92 cells,
respectively. These reductions in H4-K8-Ac correlated with NK cell lytic function as
measured by NKCA and intracellular perforin levels in NK cells. Further others show
GCs alter epigenetic patterns through recruitment of HDACs, thus this was investigated.
Findings show decreased global H4-K8-Ac patterns in NK cells were associated with
increased nuclear localization of HDAC2, suggesting that GCs recruit HDAC2 into the
nucleus causing decreased global H4-K8-Ac and NKCA. These data identify decreased
global H4-K8-Ac and increased nuclear localization of HDAC2 as potential markers of
decreased NK cell lytic activity in women experiencing psychosocial distress. This
mechanistic insight advances the field of psychoneuroimmunology by identifying both an
epigenetic modification (H4-K8-Ac) and a chromatin remodeling protein (HDAC2) as
indicators of GC mediated immune dysregulation in NK cells of women experiencing
psychosocial distress.

xii

CHAPTER 1
INTRODUCTION
It is well-established that neuro-chemical pathways link the brain and the immune
system and provide biological pathways whereby one’s emotions influence immune
function. The effect of psychological stress on immune function has been, in part,
attributed to elevations in glucocorticoids (GCs) produced by activation of the
hypothalamic-pituitary-adrenocortical (HPA) axis [1-3]. GCs can suppress Natural Killer
(NK) cell lytic activity [4-6] and alter cytokine balance [7-12].
Previous work has shown that the diagnosis of breast cancer can result in
increased psychological stress, HPA activation and altered NK cell function [5, 13-17].
For early stage breast cancer patients, a tumor is removed and prognosis is good, but the
disease can recur after apparent successful eradication of the tumor. Recurrence occurs
in some women but not in others [18]. The reasons are unclear and certainly are multiple,
but alterations in NK cell function could be a contributing factor.
However, the molecular mechanism linking psychological stress and GCs to
reductions in NK cell function remain poorly understood. It is known, however, that GCs
affect target cells through alteration of gene transcription and this may result from
epigenetic modification of histone residues [19]. One unexplored and promising
possibility is that GCs recruit chromatin remodeling proteins leading to global epigenetic
modifications resulting in NK cell dysregulation. Understanding the alterations in
epigenetic modifications and chromatin remodeling proteins associated with these
1

2

modifications will allow for a mechanistic understanding of the effects of stress upon the
immune system and is the focus of this dissertation work.

CHAPTER 2
BACKGROUND
Breast Cancer and Psychological Consequences:
Cancer affects a large number of Americans each year, with an estimate of
over 1.5 million Americans diagnosed with cancer in 2011 [20]. Of these cancer
cases, over 230,000 were breast cancer, making breast cancer the most frequently
diagnosed malignancy in the Western world [20, 21]. In American women, it is the
second leading cause of cancer death, with over 40,000 American women dying of
breast cancer yearly [20]. There is clear evidence that a diagnosis of breast cancer can
have short- as well as long-term psychological consequences [22], characterized by
increased perceived stress, depressive mood and anxiety [5, 13-17]. Increased mood
disturbance and increased fatigue also accompany a psychological stressor, such as the
diagnosis of breast cancer [15, 23-25]. These psychological consequences, termed
psychosocial distress, are independent of disease state, as women with early stage
breast cancer, as well as women with metastatic disease both report increased
psychosocial distress [15, 26, 27]. Additionally, previous work from this laboratory
found that women who underwent breast biopsy had increased perceived stress
regardless of biopsy outcome [15]. These results demonstrated that breast cancer
diagnosis resulted in a psychological and emotional response, termed psychosocial
distress in this dissertation work.
3
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The dynamics of psychosocial distress are influenced by the durationof the
stressor (i.e. either acute or chronic). Acute stressors last for minutes to hours,
whereas chronic stressors lasts months to years [28, 29]. Acute stressors can
redistribute immune cell trafficking and even increased NK cell function [30-32],
whereas prolonged chronic stress can dysregulate immune function and undermine
health [33-36]. Further, depending upon the condition of the stressor or the nature of
the neuroendocrine response to the stressor, the immune system can be reduced or
alternatively activated in its function [37, 38]. The impact of psychosocial distress on
immune function is further discussed below (See Psychosocial Distress and Immune
function). Additionally, there are variations in both the intensity and duration of
psychosocial distress reported in individuals with breast cancer [39]. For some
individuals the diagnosis of breast cancer activates appropriate allostatic responses.
Allostasis is defined as “the active process of responding to a challenge to the body by
triggering chemical mediators of adaptation” [40]. Thus, in some women the
diagnosis of breast cancer causes an initial, appropriate emotional and biological
response, which subsides allowing the body to both adapt to the stressor and to return
to allostasis. However for others the psychosocial distress is too great resulting in
increased allostatic load. Allostatic load is the “wear and tear on the body and brain
that results from chronic dysregulation (over activity or inactivity) of mediators of
allostasis” [40]. Approximately 80% of women with breast cancer report some
psychosocial distress experienced during the initial treatment phases [41].

5

Additionally, an association between increased allostatic load due to early life
adversity and breast cancer occurrence has been indentified [42]. Individual variation
makes understanding the psychosocial distress that accompanies breast cancer
diagnosis even more complex. For some individuals psychosocial distress subsides
after the initial cancer diagnosis, for others it continues beyond treatment and recovery
from the disease [43, 44].

Glucocorticoids: Mediators of Psychosocial Distress:
Psychosocial distress leads to activation of the hypothalamic-pituitaryadrenocortical (HPA) axis and the secretion of glucocorticoids (GCs) [1, 2]. GCs,
such as cortisol, have been shown to affect a number of biological systems, including
the immune system. GCs are postulated to alter thousands of different cellular genes
[45], including many immune effector genes. GCs exert effects on immune cells by
binding to glucocorticoid receptors (GRs), which are present on all immune cells [33,
34, 46]. GR is a ligand activated transcription factor, which is a member of the
nuclear receptor super family of proteins. It predominantly exists within the
cytoplasm, but when ligand activated, GR translocates to the nucleus [47]. Once in
the nucleus activated GR can alter gene transcription through recruitment of
transcription factors, co-regulators and chromatin remodeling proteins [48-51]. These
interactions between activated GR and other cellular proteins are discussed later (See
HDACs, HATs and Glucocorticoids). Under normal conditions GCs are regulated by

6

both the nervous and endocrine systems maintaining homeostasis resulting in proper
immune cell function. Individuals experiencing psychological distress exhibit HPA
activation and elevations in cortisol. If the stress perception is chronic, disruption of
the diurnal cortisol rhythm is observed [52, 53], resulting in elevated circulating GCs
[33, 34, 46].
A typical diurnal cortisol rhythm is characterized by an initial spike
approximately 15-45 minutes after waking, this initial spike it termed the cortisol
awaking rise (CAR) [54]. Cortisol levels then gradually subside throughout the course
of the day, reaching a minimal level in the evening, just prior to bedtime. Increases in
psychosocial distress have been linked to alterations in diurnal cortisol rhythms, which
can lead to immune cell dysregulation [52, 53]. However, studies have found
differential interplay between cortisol and psychosocial distress. Some groups found
increased CAR with increased activation of the HPA [55, 56] and increased
psychological stress and depressive mood [57]. Another found relationships between
increased evening cortisol levels and increased mood disturbance in breast cancer
survivors [58]. In these studies increased cortisol levels were related to increased
psychosocial distress.
However, other studies have measured decreased or blunted cortisol responses
in relationship to psychosocial distress. Analysis of total cortisol levels measured
throughout a diurnal rhythm is termed area under the curve. Women with metastatic
breast cancer, who report increased perceived stress, have decreased area under the
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curve [52, 59-61] . Similar findings were found in caregivers, with increased
depressive mood relating to a decreased cortisol response, throughout the day and
CAR[62].

Psychosocial Distress and Immune Cell Function:
A large number of studies have shown that psychosocial distress and GCs
negatively impact immune function [63-67]. Psychological stress has been shown to;
alter cytokine production [14, 15, 64, 68, 69], decrease proliferative response to
mitogens [70-72], reduce specific antibody responses, reduce T-lymphocyte mediated
cellular responses [73], and decrease synthesis of interferon gamma (IFN gamma) [15,
74, 75]. In these studies multiple different psychological stressors were related to
altered immune cell function. Such stressors included caregiving stress (individuals
caring for patients with Alzheimer’s disease), post-traumatic stress disorder, exam
stress and the diagnosis of breast cancer. Such observations coupled with the wellestablished immunosuppressive effect of GC [76], suggest an explanation for the
reduced immune function associated with increased psychosocial distress.
However, even though GCs are known to inhibit aspects of immune function
under some conditions, psychosocial distress and GCs under other conditions can
promote immune responsiveness [77-81]. Psychological stress has been shown to
increase circulating levels of tumor necrosis factor alpha (TNF alpha) and interleukin
one beta (IL-1 beta) levels in humans [82] and in rodents to increase circulating IL-1
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beta and IL-6 [83, 84]. Moreover, GCs have been shown to synergistically enhance the
induction of acute-phase proteins by IL-1 beta and IL-6 [85] and the biological effects
of IL-2, IFN gamma, granulocyte colony-stimulating factor, granulocyte macrophage
colony-stimulating factor, and oncostatin M [86]. These immune modulating effects
of GC are concentration and time dependent [87, 88] and it has been clear for many
years that the effect of the nervous and endocrine system on the immune system are
not necessarily suppressive. Substantial evidence demonstrates GC concentrations
support the activity of the immune system in a permissive and preparative manner
[89, 90].

Natural Killer Cells and Psychosocial Distress:
NK cells are multi-functional lymphocytes that do not require a pre-activation
process and are not restricted to antigen presentation by major histocompatibility
complex molecules [91, 92]. Their rapid action places NK cells as a front line of defense
against cancer and infectious agents [93-95]. Considerable attention has been paid to the
direct anti-tumor activities of NK cells [96] and evidence has existed for some time for
their role in tumor protection. Moreover, direct evidence has shown these cells to be
involved in immune surveillance, controlling the initiation and growth of tumors [97104]. NK cells produce their effects against tumor cells by first engaging the tumor
target, followed by exocytosis of NK cytolytic granule constituents against the tumor cell,
disengagement of the tumor cell by the NK cell and lysis of the tumor targets [91, 92].

9

Reciprocal neuro-chemical pathways and shared receptor systems link the brain
and the immune system, including NK cells. In particular, NK cell activity (NKCA) is
especially responsive to the impact of psychosocial distress and ample evidence
demonstrates that psychological stress or negative affective states reduce NKCA [15, 63,
105] and result in a poorer NK cell response to cytokines [71, 106]. Specifically in
individuals experiencing the diagnosis of breast cancer, increases in perceived stress were
predictive of decreased NK cell lytic activity [71, 72]. In this same study NK cells were
also less responsive to known NK stimulators, such as IFN gamma. An altered cortisol
rhythm predicted NKCA in women with breast cancer [53], with the levels of distress
correlating inversely with NKCA [107]. As these women recovered from regional breast
cancer (8-18 months after diagnosis) distress subsided and NKCA improved [107]. This
same group also investigated if NKCA dysregulation was related to altered expression of
NK cell inhibitory receptors [108]. Although, differential inhibitory molecule expression
was measured, relationships between the expression of receptors and psychosocial
distress mediated reductions in NKCA were not found. Additionally, optimal NK cell
function is especially important to women with breast cancer, as NK cell function has
been linked to increased survival in individuals with metastatic disease [109-115].
Hence, the elevations in psychological distress in response to a diagnosis of breast cancer
and subsequent reduction in NK cell function may compromise cancer outcomes and/or
increase risk of cancer reoccurence. Despite these numerous links between psychosocial
distress, GCs and NK cell function, molecular mechanisms of NK cell dysregulation in
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response to psychological distress remain poorly understood. Understanding molecular
mechanism(s) contributing to alterations in NK cell function in woman experiencing
psychosocial distress can lead to the development of approaches to enhance NK response;
thereby improving disease prognosis.

Epigenetics: Histone Modifications:
One potential mediator of NK cell dysregulation in response to psychosocial
distress is epigenetic alterations. The term epigenetic was first introduced in the 1940s.
A current working definition of epigenetic is “molecular or cellular alterations, which
influence gene expression, and by extension physiology and behavior without causing
alterations to the DNA sequence itself” [116, 117]. The epigenetic code can now be
divided into three major parts; DNA methylation, histone modifications and non-coding
RNAs [117]. All of these epigenetic modifications can regulate gene transcription
without altering DNA sequence. The following will focus on a discussion of histone
modifications.
Histone proteins H2A, H2B, H3 and H4 dimerize to form an octomeric histone
core protein [118]. Approximately 147 base pairs of DNA wrap around the histone core
proteins forming the nucleosome particle. The histone proteins, possess highly basic
amino-terminal tail domains located outside of the core nucleosome particle, which are
accessible to multiple post-translational covalent modifications [119]. These
modifications include acetylation, phosphorylation, methylation, sumoylation and
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ubiquitination [120]. Depending on the modification, these can either lead to activation
or repression of genes. Generally, acetylation has been shown to be a mark of activation,
whereas methylation is a mark of repression [121, 122]. Hyperacetylated genes are
actively transcribed, whereas hypermethylated genes are repressed.

Reversible

acetylation of the epsilon amino group of lysine is a dynamic process that regulates
chromatin structure [123]. Lysine acetylation neutralizes histone proteins, whereas
deacetylation restores the positive charge of lysines. Following deacetylation, interactions
between positively charged lysines and the negatively charged DNA phosphodiester
backbone, stabilize the DNA/histone complex, restricting nucleosome mobility on the
DNA, and hindering accessibility of the promoter to transcription machinery [124]. Thus,
deacetylated lysine residues restrict access of transcription factors for regulatory regions
of immune effector genes. By repressing a downstream target of transcription factor
activation (chromatin accessibility), GCs reduce gene expression irrespective of the exact
transcription factor requirement for an individual gene.
Histone acetylation patterns are altered throughout immune cell differentiation
and this is best characterized in the T lymphocyte populations. One study found that
alterations in cytokine profiles of T lymphocytes related to altered histone 3 (H3) and
histone 4 (H4) acetylation patterns [125]. Specifically differentiation of naïve CD4+ T
lymphocytes into either Th1 or Th2 lymphocytes resulted in a dynamic interplay between
acetylation patterns of H3 and H4. In Th1 lymphocytes increased acetylation of the IFN
gamma loci occurred, while in Th 2 lymphocytes increased H3 and H4 acetylation of the
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IL-4 loci occurred. In CD8+ T lymphocytes connections between H3 acetylation and
cytotoxicity have been demonstrated. One study provided evidence that H3-K9-Ac
contributed to production of cytotoxic molecules such as granzyme B and perforin [126].
Increases in H3-K9-Ac were related to increased promoter accessibility and increased
protein production of granzyme B and perforin.
Associations between NK cells and histone acetylation patterns are less well
characterized. There is evidence that H4 acetylation affects cell surface molecules, such
as inhibitory or activating molecules [127]. This effect is most dramatic with selective
deacetylation at histone 4 lysine position 8 (H4-K8), resulting in suppressed gene
transcription [48, 127-129]. Additionally, alterations in H4-K8-Ac have also been linked
to altered chromatin accessibility [130]. The effects of histone acetylation patterns on
chromatin structure and on immune response genes are reversible with histone
deacetylase (HDAC) inhibitors, such as Trichostatin A (TSA) [131-133]. Examination of
H3 and H4 acetylation patterns in relationship to NK cells cytotoxcity and proinflammatory cytokines remains to be determined.

HDACs, HATs and Glucocorticoids:
Two classes of enzymes are responsible for acetylation patterns of histones;
HDACs and histone acetylases (HATS). HDAC activity, either directly or indirectly,
affects expression of at least 1,120 genes [134]. HDACs are enzymes that remove acetyl
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groups from the epsilon amino group of lysines on the N-terminal tails of histone proteins
[135]. HATs transfer acetyl groups onto lysine residues of histone tails [136, 137].
HDACs are divided into four major classes, Class I – Class IV, based on their homology
with yeast orthologs. Class I HDACs include HDAC 1, 2, 3, and 8. While HDAC 1, 2,
and 3 are ubiquitously expressed, HDAC8’s activity is limited to smooth muscle [138,
139]. Class II-IV are less well characterized with regard to transcriptional repression and
in some cases are more restricted in their expression. Additionally, HDACs 1, 2 and 3
can be recruited by GR [49-51] leading to transcriptional repression [140]. Work by
Hong et al. found that cochaperone, Bcl-2 associated athanogene 1 (Bag-1) interaction
with GR led to transcriptional down regulation by recruitment of nuclear receptor corepressor (NcoR) and silencing mediator for retinoic acid and thyroid hormone receptor
(SMRT), along with HDAC3. This complex is critical for down regulation of known GC
response genes. Work from this laboratory has shown that GC treatment of an NK cell
line resulted in HDAC1 and SMRT co-localization with GR in NK cells with decreased
lytic activity [49]. Others found a new Class I specific HDAC inhibitor which measured
increased NK cell lytic activity of human PBMCs at low nanomolar concentrations,
suggesting that HDAC1, 2 and 3 are involved in regulation of NK cell lytic activity
[141]. These data suggest that alterations in Class I HDACs can lead to altered NK cell
lytic activity. However, connections between class I HDACs and global histone
acetylation patterns in NK cells remain to be determined.
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There are limited connections between HDACs and psychological stress with
most investigation in experimental animals. One study in mice did find evidence that
early life stress alters class I HDACs and histone acetylation [142]. In that study, mice
which experienced infant maternal separation had decreased expression of class I
HDACs. This decrease in expression of class I HDACs related to increased acetylation
of H4 in the brain of those mice that experienced early life stress when compared to mice
that did not. Acetylation status of H4 in the immune cells of these mice was not
investigated. Nevertheless this study did suggest that alterations in class I HDACs can
lead to altered H4 acetylation. Investigation into GCs, HDACs and psychosocial distress
in humans remains to be determined.
Other data suggest that GCs can up-regulate gene expression. This can occur by
displacing resident HDACs from gene promoter regions, allowing for histone acetylation
and transcriptional activation. One such study showed that 24 hour treatment with Dex
reduced nuclear expression of HDAC3 [143]. Additionally, interaction of the GR with
target genes can lead to transcriptional activation via recruit of co-activators and HATs
[144-146]. HATs are usually divided between type A and type B depending on cellular
localization [147]. Enzymes such as p300, CPB and pCAF have intrinsic HAT activity.
Additionally, p300 has been shown to interact with nuclear factors (NF kappa B) [146,
148], which regulate NK cell lytic activity genes (perforin and granzyme B).
Additionally, in vitro treatment with a synthetic GC (dexamethasone) increased p300
HAT activity [143]. These data demonstrate clear evidence of interaction between
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HDACs and GCs. However, how these factors interact in NK cells of women
experiencing psychosocial distress is still unknown. Further understanding of global
acetylation patterns and chromatin remodeling protein patterns in women experiencing
psychosocial distress will allow for a critical assessment of epigenetic mechanisms that
may mediate immune dysregulation.

CHAPTER 3
SIGNIFICANCE
Increased psychosocial distress is well documented in women with breast cancer.
These increases in psychosocial distress lead to HPA activation, which can alter immune
cell function, with NK cell function found to be especially responsive to these alterations.
Investigation into potential molecular mechanisms (epigenetic modifications and
chromatin remodeling proteins) of NK cell dysregulation will provide an important step
in understanding the effects of psychosocial distress on the immune dysregulation that
accompanies a diagnosis of breast cancer. Further understanding of global epigenetic
modifications and chromatin remodeling proteins could serve as a model for development
of methods for immune enhancement of individuals during periods of psychological
stress.
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CHAPTER 4
AIMS AND HYPOTHESIS
Overall Aim: Determine whether global NK cell epigenetic pattern is associated with the
immune dysregulation that accompanies the psychosocial distress of breast cancer
diagnosis.

Specific Aim 1. Characterize an in vitro system to identify effects of GCs treatment on
global epigenetic pattern and immune cell function.
Hypothesis 1a. Dexamethasone treatment of NK92 cells will alter NK cell
function; lytic activity and cytokine production.
Hypothesis 1b. Dexamethasone treatment of NK92 cells will alter global
epigenetic patterns.

Specific Aim 2. Characterize the chromatin remodeling proteins associated with global
epigenetic patterns observed in NK92 cells treated with the glucocorticoid,
dexamethasone.
Hypothesis 2a. Global epigenetic patterns of NK92 cells will be associated with
the cellular localization of chromatin remodeling proteins that repress
transcription (HDACs).
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Hypothesis 2b. Global epigenetic patterns of NK92 cells will be associated with
the cellular localization of chromatin remodeling proteins that activate
transcription (HATs).

Specific Aim 3. Characterize the global epigenetic patterns and the intracellular
localization of chromatin remodeling proteins of the NK cells of women as they respond
to and recover from breast cancer diagnosis.
Hypothesis 3a. Global NK cell epigenetic patterns will differ among women who
exhibit psychosocial distress mediated immune dysregulation and those who do
not.
Hypothesis 3b. Global epigenetic patterns will relate (correlate) to the immune
functional activity of the NK cells of women as they respond to and recover from
breast cancer diagnosis.
Hypothesis 3c. The cellular localization of chromatin remodeling proteins will
differ among the NK cells of women who exhibit psychosocial distress mediated
immune dysregulation and those who do not.

CHAPTER 5
MATERIALS AND METHODS
Natural Killer Cell Assay (NKCA):
NK cell function was assessed by NKCA. NK cell lytic activity against tumor
targets was assessed and analyzed using a standard chromium release assay, as previously
described [15]. K562 tumor cells were radioactively labeled with 100 uCi of [51Cr] (New
England Nuclear, Boston, MA). Radiolabeled K562 cells were incubated for 4 hour with
peripheral blood mononuclear cells (PBMCs) or 3 hours with NK92 cells. Following
incubation, the supernatants were removed using a Skatron harvesting press (Skatron
Inc., Sterling, VA) and the associated radioactivity was determined. NK92 cell effector
to target ratios for NKCA was 3, 2, 1 and 0.5:1. PBMCs effector to target ratios for
NKCA were 50, 30, 20 and 10:1.
Results were expressed as % cytotoxicity and calculated by the formula:
% Cytotoxicity =

(experimental DPM*) - (minimum DPM)

x

100.

_________________________________
(maximum DPM) - ( minimum DPM)
All experimental means were calculated from triplicate values. Lytic units (LU) were
calculated by a program written by David Coggins, FCRC, Frederick, MD and represents
the number of cells per 107 effectors required to achieve 20% lysis of the targets.
*DPM=disintegrations per minute.
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Cytokine Production (ELISA):
NK92 (2.5 x 105 cells/ml) cells were incubated in 24 well plates for 24 hours at 37
0

C. All molecules were measured using quantitative sandwich enzyme immunoassay

techniques (Quantikine kits, R & D Systems, Minneapolis, MN). Sensitivities for
cytokines were; (interleukin-6 (IL-6) <0.7 pg/ml, interferon gamma (IFN gamma) <3
pg/ml, tumor necrosis factor alpha (TNF alpha) <1.6 pg/ml, and Perforin<40 pg/ml). The
coefficient of variation ranged between 2.6 – 8.1% for the individually assessed
molecules.
PBMCs were unstimulated or stimulated for 48 hours with phorbol 12-myristate
13-acetate (PMA) and phytoheamagglutin (PHA) (Sigma Aldrich, St. Louis, MO). PMA
is a phorbol ester that is a polyclonal activator of PBMCs through activation of protein
kinase C which leads to protein production. PHA is able to crosslink proteins expressed
on the surface of PBMCs causing stimulation. After 48 hours, supernatants were
collected and an ELISA was performed.

Intracellular Staining by Flow Cytometry:
PBMCs:
PBMCs were aliquoted into fluorescent activated cell sorting (FACS) tubes
(500,000 cells/tube). Surface staining antibodies were added for 30 minutes on ice,
agitated every 15 minutes to identify PBMC sub populations. Dilutions for all antibodies
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(surface, intracellular and intranuclear) when appropriate was recorded in Supplemental
Table 3, antibodies not recorded in table were added neat. Surface antibodies used
included anti-CD4 (Pacific Blue conjugated), anti-CD8 (PerCP-Cy5.5 conjugated), antiCD56 (APC conjugated), anti-CD56 (PE conjugated), anti-CD45RO (APC conjugated),
anti-CD3 (APC-Cy7 conjugated) and anti-CD14 (APC conjugated) (BD Pharmingen, San
Jose, CA). PBMC sub populations were identified as: CD4+ T lymphocytes (CD4+,
CD8-, CD56-), CD8+ T lymphocytes (CD8+, CD4-, CD56-), Natural Killer (NK) cells
(CD56+, CD4-, CD8-) and CD14+ Monocytes (CD14+). Following surface antibody
staining, the cells were washed twice with 0.1% bovine serum albumin (BSA) (Sigma
Aldrich, St. Louis, MO) in phosphate buffer solution (PBS) (Gibco, Grand Island, NY).
PBMCs were fixed and permeabilized with Cytofix/Cytoperm solution (BD Pharmingen,
San Jose, CA) for 20 min at 4°C. The cells were then washed twice with Perm/Wash
Buffer (BD Biosciences, San Jose, CA) and probed with antibodies specific for
intracellular molecules of interest for 1 hour at 4°C.
For histone residues, anti-acetylated (Ac)-histone 4 lysine 8 (H4-K8) (Millipore,
Temecula, CA) (unconjugated), anti- H3K9-Ac (Alexa 488 conjugated) (Cell Signalling
Beverly, MA), anti-trimethylated (me3)-H3K4 (unconjugated ) (Cell Signalling Beverly,
MA), anti-phosphorylated (P)-H3S10 (Alexa 488 conjugated) (Cell Signalling Beverly,
MA) were added to cells in FACS tubes. The cells were washed twice with Perm/Wash
Buffer (BD Biosciences, San Jose, CA), after which secondary anti-immunoglobulin
gamma (IgG) (FITC conjugated) (Millipore, Temecula, CA) was added for 30 min at 4°C
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to the H4-K8-Ac and H3-K4-me3 tubes. Following this treatment, the cells were washed
twice with Perm/Wash Buffer (BD Biosciences, San Jose, CA) and resuspended in 0.1%
BSA (Sigma Aldrich, St. Louis, MO) in PBS (Gibco, Grand Island, NY).
For intracellular cytokine analysis, cells were permeabilized and then incubated
with antibodies specific for intracellular proteins for 1 hour at 4°C. Antibodies for
intracellular staining used included anti-IFN gamma (PE conjugated) (BD Biosciences,
San Jose, CA), anti-granzyme B (Alexa Fluor 647 conjugated) (BD Biosciences, San
Jose, CA), anti-TNF alpha (PE-conjugated) (BD Biosciences, San Jose, CA), anti-TNF
alpha (Alexa 488-conjugated) (BD Biosciences, San Jose, CA), anti-IL-6 (PE conjugated)
(BD Biosciences, San Jose, CA) and anti-perforin (PE conjugated) (BD Biosciences, San
Jose, CA). For intracellular cytokine analysis of IFN gamma and TNF alpha, cells were
incubated in leukocyte activation cocktail (LAC) (BD Pharmingen, San Jose, CA) at
37°C for 4 hours prior to permeabilization and antibody staining. LAC contains PMA,
ionomycin and brefeldin A. PMA is a phorbol ester which is a polyclonal activator of
PBMCs, ionomycin is a calcium ionphore which increases calcium levels in the cell
resulting in PBMC stimulation. Brefeldin A is a protein transport inhibitor which
allowed for intracellular assessment of cytokines. For intracellular cytokine analysis of
IL-6, cells were incubated in leukocyte activation cocktail (BD Pharmingen, San Jose,
CA) and 100 ng of sonicated lipopolysaccharide (LPS) (Sigma Aldrich, St. Louis, MO) at
37°C for 4 hours prior to permeabilization and antibody staining.
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For chromatin remodeling protein analysis, cells were permeabilized and then
incubated with antibodies specific for chromatin remodeling protein for 1 hour at 4°C.
For chromatin remodeling proteins, cells were probed with antibodies specific for histone
deacetylase 1 (HDAC1) (Alexa-647-conjugated) (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA), HDAC2 (unconjugated) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA),
phosphorylated-HDAC2 (unconjugated) (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA), HDAC3 (unconjugated) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), p300
(Alexa 647-conjugated) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Secondary
anti-IgG (FITC conjugated) (Millipore, Temecula, CA) was added for 30 min at 4°C to
unconjugated primary antibodies.
For all PBMCs, cytokine and histone mean fluorescent intensities (MFIs) were
standardized to cytokine and histone MFIs of HiCK Control Cells (BD Pharmingen, San
Jose, CA). Surface antibodies were not added to HiCK Control Cells; intracellular and
histone antibodies were added as described above. HiCK Control Cells were thawed and
aliquoted into individual microcentrifuge tubes before storage at -80 °C. On the day of
PBMC staining, HiCK Control Cells were thawed at 37°C for 2 minutes and then
aliqoted into FACS tubes for staining. HiCK Control Cells were stained concurrently
with PBMCs, therefore staining times, incubations and washes were identical to PBMCs.
No change in HiCK cell staining was observed over time.

For MFI calculations, the following formula was used:
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MFI= Cytokine or Histone MFI of sample/Cytokine or Histone MFI of HiCK cell.

After staining, samples were analyzed by flow cytometry with a FACS CantoII
Fluorescence-Activated Cell Sorter or a LSR Fortessa using FACS Diva software for data
acquisition [149-151]. 10,000-30,000 events were recorded and analyzed with FlowJo
v8.4.1.

NK92 cells:
NK92 cells were aliquoted into FACS tubes (0.25-1 x 105 cells/tube). Staining
protocols, lengths of incubations and antibodies used as previously described for PBMCs.
Additional antibodies used for NK92 cell staining but not PBMC staining are listed
below:
Surface staining antibodies included; anti-CD337 (NKp30) (Alexa Fluor 647
conjugated) (BD Biosciences, San Jose, CA), anti-CD335 (NKp46) (PE conjugated) (BD
Biosciences, San Jose, CA) and anti- LFA-1 (CD11a) (FITC conjugated) (BD
Biosciences, San Jose, CA). For chromatin remodeling proteins, antibodies used were
anti-glucocorticoid receptor (GR) (unconjugated) (Abcam, Cambridge, MA), and antimitogen stress kinase-1 (MSK-1)-phosphorylated (unconjugated) (Cell Signaling,
Boston, MA). Secondary anti-IgG (FITC conjugated) (Millipore, Temecula, CA) was
added for 30 min at 4°C to unconjugated primary antibodies.
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Treatment MFI= (Treatment MFI/Average MFI of No Treatment)x100

After staining, samples were analyzed by flow cytometry with a FACS CantoII
Fluorescence-Activated Cell Sorter or a LSR Fortessa using FACS Diva software for data
acquisition [149-151]. For NK92 cells 1,000-10,000 events were recorded and analyzed
with FlowJo v8.4.1.

Cellular Culture:
The human erythroleukemic like cell line, K562, was obtained from the American
Type Culture Collection, Rockville, MD. K562 cells were maintained in suspension
cultures in vitro in Corning 75 cm2 tissue culture flasks (Corning Glass Works, Corning,
NY) in RPMI 1640 (Gibco Laboratories, Grand Island, NY) supplemented with 10% fetal
bovine serum (FBS) low LPS; (Gibco Laboratories, Grand Island, NY), 100 units/ml
penicillin, 100ug/ml streptomycin (Whittaker M. A. Bioproducts, Walkersville, MD), 0.1
mM non-essential amino acids, 0.1 mM 2-mercaptoethanol and 2 mM L-glutamine
(Gibco Laboratories, Grand Island, NY). K562 cells were passaged every 48 hours with
media.
NK92 cells (established from a patient with non-Hodgkin’s lymphoma with the
capacity to lyse a broad range of leukemia, lymphoma and myeloma cell lines at low
effector to target ratio in vitro) were obtained from the American Type Culture
Collection, Rockville, MD and maintained in alpha MEM with 12.5% horse serum
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(Gibco Laboratories, Grand Island, NY), 12.5% fetal bovine serum (Gibco Laboratories,
Grand Island, NY), 100 units/ml penicillin, 100ug/ml streptomycin (Whittaker M. A.
Bioproducts, Walkersville, MD), 0.2 mM inositol (Sigma Aldrich, St. Louis, MO), 0.1
mM 2-mercaptoethanol (Gibco Laboratories, Grand Island, NY) and 0.02 mM folic acid
(Sigma Aldrich, St. Louis, MO). NK92 cell cultures were also supplemented with
interleukin-2 (IL-2) (100 units/ml). NK92 cells were passaged every 48 hours with
media and IL-2. NK92 cell viability is dependent on addition of IL-2.

NK92 Cellular Treatment Systems:
- Short-Term, High Dose (Dexamethasone 10-7M for 24 hours):
NK92s, cultured at 2.5 x 105 cells/ml, were treated with dexamethasone (Dex)
(Sigma Aldrich, St. Louis, MO) (10-7 M), for 24 hours in the absence of IL-2. NK92s
were washed with media and resuspended to 1 x 106 cells/ml for assay. In a similar
manner, NK92s were treated with Dex (10-7 M) for 24 hours and then Trichostatin A
(Cell Signaling Technology, Danvers, MA) (100 nM) (TSA) was added to cultures for 1
to 6 hours. 1 hour TSA treatments were used for NKCA, histone analysis (western and
flow cytometric) and 6 hour TSA treatments were used for intracellular IFN gamma
assays. NK92s were washed and resuspended with media to 1 x 106cells/ml. Cell number
and viability were determined by exclusion using 0.1% Trypan blue.
- Chronic Treatment (Dex 10-10 M for 5 days):
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For chronic Dex treatments, NK92s, cultured at 2.5 x 105 cells/ml, were treated with
Dex (Sigma Aldrich, St. Louis, MO) (10 -10M) for 5 days. For the first 4 days of
treatment, cells were cultured in the presence of IL-2. For the final 24 hours cells were
cultured without IL-2. Cells were counted and resuspended every 48 hours with fresh
media and Dex. NK92s were washed with media and resuspended to 1 x 106 cells/ml for
assay. Cell number and viability was determined by exclusion using 0.1% Trypan blue.

Cell Conjugation Assay:
K562 cells were suspended in 1 ml of 0.1% BSA (Sigma Aldrich, St. Louis, MO) in
PBS (Gibco, Grand Island, NY) at a final concentration of 5 x 106 cells/ml, then labeled
for 10 minutes at 37 °C with carboxyfluorescein diacetate, succinimidyl ester (CFSE) (2
uM, Sigma Aldrich, St. Louis, MO). The cells were washed 3 times with ice-cold 0.1%
BSA (Sigma Aldrich, St. Louis, MO) in PBS (Gibco, Grand Island, NY). NK92 cells
were labeled with anti-CD56 (APC-conjugated) (BD Biosciences, San Jose, CA) for 30
minutes on ice and agitated after 15 minutes. Following antibody staining, the cells were
washed twice with 0.1% BSA (Sigma Aldrich, St. Louis, MO) in PBS (Gibco, Grand
Island, NY) and resuspended in alpha-MEM media (Gibco Laboratories, Grand Island,
NY). NK92 cells at a concentration of 5 x 106/ml were mixed with 5 x 106/ml CFSElabeled K562 target cells at an effector to target ratio of 1:1, allowing the formation of
effector-target conjugates. The NK92-K562 cell mixture was centrifuged at 1,000
revolutions per minute (rpms) for 2 seconds and incubated at 37 °C for 10 minutes. Then
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the cell mixture was gently resuspended in 0.1% BSA in PBS and fixed with 1%
paraformaldehyde (PFA) in PBS (Sigma Aldrich, St. Louis, MO). The conjugation ratio
was calculated as the portion of CSFE/APC double-positive events [152].

Western Blot:
For Western Blot analysis, nuclei of NK92 cells were extracted from 1-5 x 106
cells via the Fermentas ProteoJET Cytoplasmic and Nuclear Protein Extraction protocol
(Fermentas, Burlington, ON). Nuclei were lysed using Nuclear Lysis Buffer (Fermentas,
Burlington, ON) and resuspended in Laemmelis SDS-Sample Buffer (4x) (Boston
Bioproducts, Boston, MA). Samples were boiled for 10 minutes and proteins separated
by electrophoresis with a 15% agarose gel and transferred to a nitrocellulose membrane
for blotting. Proteins were visualized with anti- H4-K8 Ac antibodies or anti-H3
antibodies (Millipore, Temecula, CA), horseradish peroxidase (HRP) conjugated anti-IgG
secondary antibody (Millipore, Temecula, CA) and chemiluminescence reagent
(ThermoScientific, Rockford, IL). Blots were standardized to total H3 protein (Cell
Signaling, Danvers, MA) and blot density quantified using Image J software.

Immunofluorescent Microscopy:
NK92 cells on glass slides:
Glass coverslips (Fisher Scientific) were sterilized with 100% ethanol (Sigma
Aldrich, St. Louis, MO). Coverslips were treated with Cell Tak poly-L-lysine (BD
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Biosciences, Bedford, MA) for 10 minutes to aid adherence of NK92s to coverslips. Dex
treated and untreated NK92 cells (500,000 cells/coverslip) were added to the coverslips
for 10 minutes. Coverslips were treated with methanol-free formaldehyde (Polysciences
Inc., Warrington, PA) diluted in saponin buffer (Sigma Aldrich, St. Louis, MO) for 10
minutes. This fixed cells to coverslips while maintaining 3D structure of cells. Coverslips
were washed with PBS. Cells were permeabilized with 0.2% Triton-X (Sigma Aldrich,
St. Louis, MO) for 12 minutes. Coverslips and cells were blocked for 15-60 minutes with
0.1% BSA in PBS. Next, antibodies specific for chromatin remodeling proteins were
added for 1 hour at room temperature. Primary antibodies were added at a 2.5:100
dilution in 0.1% BSA in PBS. Antibodies used included: anti-HDAC1 (Cell Signaling,
Danvers, MA) (Abcam, Cambridge, MA), anti-HDAC2 (Cell Signaling, Danvers, MA),
anti-HDAC3 (Cell Signaling, Danvers, MA) (Abcam, Cambridge, MA) and anti-GR
(Abcam, Cambridge, MA). Coverslips were washed with 0.1% BSA in PBS. After
primary antibodies, secondary antibodies were added for 20-30 minutes at room
temperature. Secondary antibodies were added at a 1:500 dilution. Secondary antibodies
to be used were: donkey-anti-mouse IgG (Cy3-conjugated) (Jackson Immunoresearch,
West Grove, PA) and donkey-anti-rabbit IgG (Alexa 488-conjugated) (Jackson
Immunoresearch, West Grove, PA). Coverslips were washed with 0.1% BSA in PBS.
After washing coverslips were fixed to slides with Prolong Gold (Invitrogen, Carlsbad,
CA) containing DAPI stain for nuclear identification. Images were collected with a
DeltaVision microscope (Applied Precision) equipped with a digital camera (CoolSNAP
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HQ; Photometrics), using a 1.4-numerical aperture 100× objective lens, and were
recorded with SoftWoRx software (Applied Precision). Images were assessed and
analyzed with Imaris Software.

NK92 Cells- Image Stream:
Cellular permeabilization, reagents and antibody staining procedures as described
above in Intracellular Staining by Flow Cytometry Section. After staining, samples were
analyzed by immunofluorescent microscopy with an Amnis Image Stream for data
acquisition. For NK92 cells 500-3,000 events were recorded and analyzed with IDEAS
Software.

Recruitment/Enrollment:
Women 43-75 years of age, with early stage, breast cancer, treated with breast
conserving surgery were enrolled. Some women also underwent radiotherapy and/or
hormonal therapy. Women were excluded if they were treated with systemic
chemotherapy, had recurrent breast cancer or other cancers (within the last 5 years),
immune-based disease (e.g. multiple sclerosis, HIV), psychoses, cognitive dysfunction;
were not fluent in English, abused controlled substances, were under psychotherapy, took
anxiolytics, hypnotics, psychotropics, cortico-steroids, or immune-altering drugs. At
each time point subjects were screened for infections. These criteria applied equally to a
Comparison Group (Control).
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Missing data were minimal for both psychological and immune data. Reasons for
missing immune data were inadequate specimen blood volume, inability to perform
venipuncture or frank refusal of venipuncture.

Study Outline:
For all women enrolled psychological instruments were administered, salivary
cortisol was collected and peripheral blood was obtained. Women were assessed as they
responded to and recovered from breast cancer diagnosis at four time points (See Figure
13). Data were collected in the period of initial cancer diagnosis (T1), 10-12 days post
breast surgery and before any adjuvant therapy was initiated (T2). An interval of 10-12
days after surgery provided ample time for surgical or anesthesia-induced effects to
dissipate [110, 153-162]. Hence, this window of time permitted analysis of variables
without confounds of surgery or adjuvant therapy. The third time point (T3) was two
months following radiation treatment completion (for those receiving radiation treatment)
or approximately four months after diagnosis (for those not receiving radiation treatment)
and the fourth time point (T4) was six months after radiation treatment completion (for
those receiving radiation treatment) or approximately 8 months after diagnosis (for those
not receiving radiation treatment). PBMCs were isolated from blood specimens obtained
from these women by a ficol histopaque gradient density separation, as described
previously [151].
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Psychological Assessments:
Women completed the Perceived Stress Scale (PSS), which provided a general
measure of stress (i.e., controllability of life events). Women with breast cancer may
exhibit depressive symptoms, so the Center for Epidemiologic Studies–Depression (CESD) was administered, which captured depressive symptoms, as well as monitored for risk
of depression. PSS is a 10-item scale that assesses the degree to which a person finds
their lives as unpredictable, uncontrollable or overloaded (i.e., exceeding their adaptive
capacities). It is a measure of global stress appraisal, as opposed to a specific event which
evokes a stress response [163]. Reliability (stability) was 0.85 and Cronbach alphas range
from 0.75-0.86 [164]. The PSS is widely used in studies of stress on immunity, including
studies of the stress-immune response of women with breast cancer [15, 107]. PSS was
shown to be strongly related to trajectories of change in NKCA observed in women as
they adapted to a diagnosis of breast cancer[107]. CES-D provided a measure of
depressive symptoms. CES-D assesses frequency and duration of depressive symptoms
[165]. Scores range from 0-60 and >16 suggests depression risk. CES-D is widely used in
studies of women with breast cancer [166, 167]. It has good construct validity, good testretest reliability [165]. In cancer patients and healthy controls CES-D showed good
internal consistency (alpha=0.87 and alpha=0.89), respectively [168].

Selection Criteria- Cancer Pre, Cancer Post, Control:
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The response to breast cancer diagnosis as assessed by the PSS is quite individual
and varied for the cohort evaluated, as part of this dissertation. For example, 28% of the
Cancer group reported PSS scores that did not change from T1 and T2. Whereas, PSS
scores decreased from T1-T2 for 40% of the Cancer group while 32% of the Cancer
group reported an increase in PSS from T1-T2. These variations in PSS overtime are
common in individuals with cancer [39] as individuals vary in their perception of stress,
coping effectiveness, and supportive networks. In order to capture results during the
peak of perceived stress for these women at T1 and T2, a selection technique was used to
identify a pre radiation time point at which an individual woman expressed the greatest
level of perceived stress and in addition also demonstrated reduced NKCA. The rationale
for inclusion of reduced NKCA as additional criteria is that NKCA is highly sensitive to
the effects of perceived stress [5, 109-114]. For each woman the time point (either T1 or
T2) where increased PSS and decreased NKCA were measured was selected for the
Cancer Pre group. In some Cancer women decreased stress and/or increased NKCA was
observed at T1 and T2, for these women the time point where the higher PSS and lower
NKCA was used (see Supplemental Table 7). This resulted in 27 women selected for
T1 or T2 time periods out of the total 29 women. The remaining 2 women were not
included in this evaluation. This selection technique was used by other groups as well to
assess women with increased PSS and decreased NKCA [108, 169]. Limited numbers of
women enrolled in the Cancer group prevented assessment of a separate group of patients
exhibiting low PSS and low NKCA.
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The Cancer Post group assessed Cancer women following radiation treatment.
For the Cancer Post group either the T3 or T4 time points were chosen that reflected
decreased PSS. Limited sample size prevented selection based on NKCA. This resulted
in 20 Cancer women selected from T3 and T4 time period out of a total of 22 women.
The remaining 2 women were not evaluated. The Cancer women used for the Cancer Pre
group were the same Cancer women used for the Cancer Post group, simply following
therapeutic treatment. For each woman either the T3 or T4 was included. Additionally,
availability of psychological and immune data also determined which time point was
assessed. For the Control group psychological assessments remained consistent
throughout the study and thus one group was created (Control).

Salivary Cortisol:
Women collected saliva for measurement of cortisol two days prior to a blood
draw at each time point. On each of the two collection days, saliva was obtained at
awakening (“when your eyes open and you are ready to get up”), at 30 minutes after
wakening, noon, 5 PM and at bedtime (“right before getting into bed”). Women recorded
collection times on saliva vials. They did not brush their teeth for at least 15 minutes
prior to collection and abstained from smoking at least 1 hour before sampling. Using
salivettes (Salimetrics™), subjects gently chewed (60-90 seconds) on a soft swab that fits
into a holder resting in a centrifuge tube. The morning sample was obtained within 15
minutes of each person’s wake time [170, 171], while compliance for the later samples
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was ± 60 min around the sampling time. Women who woke after 11 AM and night shift
workers were excluded[172]. Centrifuged samples were frozen (-200C) and assayed in
duplicate within 6 months using immunoassay kits (Salimetrics™). Intra-assay
coefficient of variation was 3.35-3.65%. Inter-assay coefficient of variation was 3.756.41%. The minimal detectable cortisol concentration was < 0.003 μg/dL. The cortisol
awakening response (the difference between the sample collected at 30 minutes and the
wakeup sample) was determined.

The waking rise was calculated with the following formula:
Waking Rise = [(Salivary Cortisol 30 minutes post wakening (ng/ul))-(Salivary
Cortisol at awakening 9ng/ul))]/[(Time 30 minutes post wakening (minutes))(Time Wakening(minutes))]

Statistical Analysis:
PBMCs:
Missing data were treated as such and no imputation techniques were used.
Independent student t test was performed to analyze differences between the Cancer
group and Control group at each time point (e.g. Cancer T1 vs. Control T1). A two-sided
alpha of 0.05 was set for statistical significance. Correlations were examined by
Pearson’s correlation coefficient with an alpha of p< 0.05 set for statistical significance.
When data sets were not normally distributed or skewed log transformations were
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performed on raw data prior to analysis. Skewness was tested by the Shapiro-Wilks test.
One-way ANOVAs with Least Significant Difference (LSD) and Bonferroni post hoc
analysis were used for statistical assessment of selected groups (Cancer Pre, Control and
Cancer Post). Statistical package for Social Sciences (SPSS: version 15.0) was used for
data analysis.
NK92 cells:
Data were expressed as means with the standard error of the mean (SEM). Main
study variables were analyzed using independent Student’s t test when two groups were
compared and one-way ANOVA followed by Tukey post hoc analysis when three groups
were compared. Pearson’s correlation coefficients were calculated for correlation
analysis. A two-sided alpha of 0.05 was set for significance, except as noted. The
Statistical Package for Social Sciences (SPSS: version 15.0) was used for data analysis.

CHAPTER 6
RESULTS
Specific Aim 1. Characterize an in vitro system to identify effects of GCs treatment
on global epigenetic pattern and immune cell function.

It is well-established that psychosocial distress reduces natural killer cell activity
(NKCA) [14, 15, 63, 105, 173] and dysregulates cytokine balance mediated by stressinduced release of glucocorticoids (GCs) [7-9]. This aim sought to identify whether GCs
(dexamethasone) reduce NK functional activity and alter cytokine production through
global epigenetic modification of histone residues. A human NK cell line (NK92 cells)
was used to identify those functional activities of NK cells that are affected by
dexamethasone (Dex). As human samples were limited, an in vitro model system
provided a screening tool for determining which global epigenetic modifications were
altered by Dex and also related to NK cell function.

Short-Term, High Dose Dex Treatment (Dex 10-7 M for 24 hours) of NK92 cells:

Effect of Dex on NKCA:
The ability of Dex to reduce NK92 cell lysis of tumor cell targets was evaluated.
Treatment of NK92 cells for 24 hours produced a dose-dependent reduction in NK92
37
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lytic activity (Figure 1). A concentration of (10-7M) Dex produced an approximate 50%
reduction in NKCA with no impact on cell viability, as judged by Trypan blue exclusion
(Supplemental Table 2).

Effect of Dex on NK92 Adhesion when Engaged by Tumor Cells:
NKCA requires first the adhesion of NK cells to a tumor cell target, followed by
the exocytosis of lytic granules, which destroy the tumor cell target. The ability of NK92
cells to form conjugates with target cells after Dex treatment was analyzed by flow
cytometry. NK92 cells were labeled with APC-conjugated antibodies specific for the NK
cell surface molecule CD56. K562 tumor targets were labeled with CFSE. NK92-K562
conjugates were measured as double positive (CD56+, CFSE+) populations. The ability
of NK92 cells to form conjugates with K562 cells was significantly (p=0.001) decreased
in response to Dex (10-7M), as compared to untreated NK92 cells, Table 1. These results
indicate that Dex reduced NKCA, in part, by reducing the capacity of NK92 cells to bind
to K562 target cells.

Effect of Dex on Production of IFN gamma and Perforin:
Experiments were conducted to assess the effect of Dex on the capacity of NK92
cells to produce effector molecules: IFN gamma and perforin. The effect of Dex on the
NK92 production of IFN-gamma and perforin production was assessed by ELISA. A
dose dependent effect was observed and Dex at 10-7M significantly inhibited constitutive
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IFN-gamma secretion (30.6 ± 1.1 pg/ml vs. 52.5 ± 1.9 pg/ml; p<0.001) and perforin (17.0
ng/ml vs. 20.5 ng/ml), Figure 2.
Following cellular activation, Dex also reduced NK92 production of intracellular
IFN-gamma. As shown in Figure 3 and Table 2, Dex (10-7 M) decreased not only the
detectable level of the cytokines on a cell-to-cell basis (32.4 ± 2.9% reduction, p<0.0001
for IFN gamma) but also the percentage of cytokine positive cells (30.9 ± 1.5%
reduction, p<0.001 for IFN gamma). In Table 2 the MFI of these detected intracellular
cytokines are presented and demonstrate a significant reduction in detectable cytokine by
Dex treatment followed by cellular activation.

Effect of Dex on NK92 Surface and Intracellular Proteins:
Since Dex treatment of NK92 cells decreased conjugate formation the effect of
Dex on the capacity of NK92 cells to produce NK adhesion and effector molecules was
next assessed by flow cytometry. Adhesion molecules allowed for proper conjugate
formation resulting in lysis of target cells. Once inside target cells the effector molecule,
granzyme B, initiates apoptotic pathways resulting in target cell death. There was a
significant reduction in the expression of the lymphocyte adhesion molecule, LFA-1
(p=0.0001), which is known to mediate binding of NK92 cells to K562 and the granule
constituent, granzyme B (p=0.022). In Table 2 MFIs of these surface markers and
granule constituent are presented. All NK92 cells stained positive for these molecules,
therefore no changes in percent positive cells were measured. Interestingly, these effects
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were not universal in that the adhesion molecule, CD2 (also know to mediate binding of
NK92 cells to K562) [174, 175] expression was not decreased. See Table 2.

Effect of Dex on H4-K8 Acetylation:
To assess the epigenetic effect of Dex, western blot analysis and flow cytometric
analysis were performed on nuclear extracts derived from NK92 cells, Figure 4, or on
permeabilized NK92 cells, Table 3. The blots and permeabilized cells were probed with
antibodies specific for H4-K8 Ac. NK92 cells treated with Dex had decreased global
acetylation of H4-K8 (~50% reduction) when compared to untreated cells as measured by
western blot. In Figure 4a, a representative western blot is presented and shows the
visual reduction in H4-K8 acetylation. Figure 4b illustrates the quantification of western
blots for the 4 groups of NK92 cells: No Treatment, Dex treated, TSA treated and Dex
plus TSA. ANOVA demonstrated a significant difference among the 4 groups,
[F(3,12)=99.526, p<0.0001], such that there was a significant reduction in acetylation of
H4-K8 with Dex, which was restored by treatment with TSA, a histone deacetylase
(HDAC) inhibitor. Dex also reduced acetylation of H4-K8 as judged by flow cytometric
analysis (~20%) Table 3. ANOVA demonstrated a significant difference among the 4
groups, H4-K8 MFI [F(3,11)=33.104, p<0.0001] and H4-K8 % NT [F(3,24)=12.918
p<0.0001] such that there was a significant reduction in acetylation of H4-K8 with Dex
which was reversed by treatment with TSA, a HDAC inhibitor. These effects of Dex
were not observed with HDAC inhibitor treatment. Western blot analysis was performed
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on nuclear extracts from NK92 cells and standardized to total nuclear histone 3 (H3)
proteins. Flow cytometric analysis evaluated nuclear acetylation of H4-K8 and was
standardized to cell number, rather than cellular H3 protein. These differences likely
account for differential reductions in H4-K8 Ac.
These global changes in acetylation suggest that the effect of Dex on NK92s was
a possible consequence of epigenetic modification to promoter regions associated with
genes essential to NK cell lytic effector function (e.g. perforin and granzyme B). If this
was true, then short-term, high dose Dex treatment would reduce accessibility for the
promoter regions of these genes, perforin and granzyme B. These epigenetic effects were
assessed by, chromatin immunoprecipitation (ChIP) with anti-H4-K8 Ac, followed by
quantitative real time PCR, was used to calculate the fold change in accessibility after
short-term, high dose Dex treatment. Short-term, high dose Dex treatment reduced H4K8-Ac at both the perforin and granzyme B promoter regions [6].

Effect of Histone Deacetylase Inhibitor (TSA) on Interferon gamma Production and
NKCA by Dex Treated NK92 Cells:
These data suggest that the alteration in NK cell functional activity after shortterm, high dose Dex treatment may result from promoter deacetylation at immune
relevant genes. If so, then treatment with TSA would be expected to modify the effects
of Dex on the functional activity of the NK cells. NK92 cells were treated with Dex,
followed by incubation with TSA. TSA modified the effects of Dex not only for the
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intracellular production of IFN gamma, Table 4, but also for NK lytic activity against
tumor targets, Table 5. ANOVA analysis showed significant differences among the 4
treatment groups [No Treatment (NT), Dexamethasone (Dex), Trichostatin A (TSA) and
Dexamethasone plus TSA] for IFN gamma MFI [F(3,15)=46.515, p<0.001] and IFN
gamma % NT [F(3,15)=49.973, p<0.0001] Table 4. Dex significantly reduced detectable
levels of IFN gamma, but with the addition of TSA, these levels returned to that of the
untreated cell population. Likewise for NKCA, Dex significantly reduced lytic activity
of NK92 cells for tumor targets and treatment with TSA returned NKCA to a level
produced by untreated NK92 cells, Table 5. ANOVA analysis showed significant
differences among the 4 treatment groups [No Treatment (NT), Dexamethasone (Dex),
Trichostatin A (TSA) and Dexamethasone plus TSA] NKCA lytic units [F(3,27)=30.770,
p<0.0001] and NKCA % NT [F(3,36)=44.110, p<0.0001].

Brief Discussion of Short-Term, High-Dose Dex Treatment of NK92 Cells:
Short-term, high-dose Dex treatment (10-7 M for 24 hrs) reduced NK cell function
and global H4-K8-Ac in NK92 cells. Although effects of short-term, high-dose Dex
treatment were dramatic and impacted both global and gene-specific acetylation changes
[6] immune functional changes do not completely reflect patterns observed in breast
cancer patients experiencing psychosocial distress and thus a second in vitro system was
investigated. Investigation into dose and duration of Dex exposure on NK92 cells was
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explored. Development of a chronic, five day treatment system allowed for increased
understanding of GCs induced epigenetic and immunologic changes in NK cells.

Chronic Dex Treatment (Dex 10-10 M for 5 days) of NK92 cells:

Effect of Chronic Dex Treatment on NKCA:
The ability of Dex to reduce NK92 cell lysis of tumor cell targets following
chronic Dex treatment was evaluated. Chronic Dex treatment of NK92 cells for 5 days
produced a reduction in NK92 lytic activity, Figure 5. A concentration of (10-10M) Dex
reduced cytotoxicity at each effector:target ratio (p<0.05) with no impact on cell viability,
as judged by Trypan blue exclusion (Supplemental Table 2).

Effect of Chronic Dex Treatment on Intracellular IFN gamma:
Experiments were conducted to assess the effect of Dex on the capacity of NK92
cells to produce the pro-inflammatory cytokine, IFN gamma. Following cellular
activation, chronic Dex treatment increased NK92 production of intracellular IFNgamma. As shown in Figure 6, Dex (10-10 M) increased the detectable level of
intracellular IFN-gamma on a cell-to-cell basis (p<0.05).

Effect of Chronic Dex Treatment on Global H4-K8 Acetylation:
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To assess the epigenetic effect of chronic Dex treatment, flow cytometric analysis
was performed on permeabilized NK92 cells. The permeabilized cells were probed with
antibodies specific for H4-K8 Ac. NK92 cells treated with Dex had decreased global
acetylation of H4-K8 (~20% reduction) when compared to untreated NK92 cells. In
Figure 7a, a representative flow cytometric blot is presented and shows the visual
reduction in global H4-K8 acetylation. In Figure 7b, the graph shows the quantification
of 3 independent experiments measuring global H4-K8-Ac by flow cytometry. Chronic
Dex treatment of NK92 cells global H4-K8-Ac MFI is standardized to untreated NK92
cells.

45

46

a

b

47

48

49

18

*

16

Untreated

% Cytotoxicity

14
12

Dex -10 M

*

10
8

*

6
4

*

2
0

2:1

1:1
0.5:1
NK92:K562 Ratio

0.25:1

50

*
IFN gamma MFI/Average IFN gamma
MFI of NT

140

No Treatment
120

Dex -10 M

100
80

60
40
20
0

IFN gamma MFI

51

a

b

***
No
Treatment
Dex -10 M

% of Max

H4K8-Ac MFI Standardized to NT

120

100

80

60

40

20

0

5 Day
H4K8-Ac-FITC

52

Table 1
Effect of dexamethasone and trichostatin A on conjugate formation of NK92 with target
cells by flow cytometric analysis.

Treatment

% Conjugates

P
value
(compared
to NT)

No Treatment
(NT)

100

Dex (10-7 M)

73.3  3.3

0.0001

TSA (100 nM)

97.32  6.0

0.975

Dex (10-7 M) + TSA (100 nM)

72.23  6.11

0.001

Data are mean values  S.E.M., n>7. Dex= dexamethasone. TSA= Trichostatin A. NT=
No Treatment. Isotype control MFI was always < 150. % Conjugates = [(No Treatment
(NT) - Dex or Dex + TSA)/ (No Treatment (NT)] X 100. Statistically significant
difference, NT vs. Dex, NT vs. Dex + TSA, Dex vs. Dex + TSA.
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Table 2
Effect of dexamethasone on surface and intracellular proteins of NK92 by flow
cytometric analysis.

Mean Fluorescent Intensity (MFI) of Surface and Intracellular Proteins

Cellular
Protein

No
Treatment

Dexamethason P value
e Treatment

% Change

P value

(10-7 M)

376  17

272  4.7

0.004

-31.6  2.8

0.0001

LFA-1

2,722  50

2,377  28

0.0001

-13.1  0.7

0.0001

CD-2

783  12

884  9.0

0.0001

12.8  1.2

0.0001

Granzyme B

63,156 
1178

57,522 
1706

0.022

-11.3  2.7

0.001

IFN gamma

Values are mean fluorescent intensity (MFI) of surface and intracellular proteins 
S.E.M., N= at least three independent experiments. Isotype control MFI was always <
150. % Change= (MFI No Treatment - MFI Dexamethasone)/(MFI No Treatment) X 100.
Statistically significant difference, No Treatment vs. Dexamethasone Treatment.
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Table 3
Effect of dexamethasone and trichostatin A on H4-K8 nuclear acetylation of NK92 by
flow cytometric analysis.

Treatment

H4K8-Ac
MFI

P
value
(compared

% NT
(compared
to NT)

to NT)

P
value
(compared
to NT)

H4K8-Ac
MFI
P
value
(compared
to Dex)

No Treatment
(NT)

2,437  18

Dex (10-7 M)

2,054  71

0.002

79.8  3.9

0.021

TSA (100 nM)

2,701  34

0.018

119.7  8.1

0.025

Dex (10-7 M) +
TSA (100 nM)

2,506  47

0.735

106.9  2.8

0.694

0.002

0.001

Data are mean values  S.E.M., n =7. Dex= dexamethasone. TSA= Trichostatin A. NT=
No Treatment. Isotype control MFI was always < 150. % of NT = [(No Treatment (NT) Dex or Dex + TSA)/ (No Treatment (NT)] X 100. Statistically significant difference, NT
vs. Dex, NT vs. Dex + TSA, Dex vs. Dex + TSA.
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Table 4
Effect of dexamethasone and trichostatin A on intracellular interferon gamma of NK92
by flow cytometric analysis.

Treatment

IFN
gamma
MFI

P
value

% NT

(compared to
NT)

P
value
(compared
to NT)

IFN
gamma
MFI
P
value
(compared
to Dex)

No Treatment

753  22

Dex (10-7 M)

563  12

0.039

74.8  1.6

TSA (100 nM)

1255  25

0.0001

166  3.3

0.0001

Dex (10-7 M)
+ TSA (100
nM)

933  78

0.051

123  10

0.043

0.039

0.032

0.0001

Data are mean values  S.E.M. N=4. Dex= dexamethasone. TSA= Trichostatin A. NT=
No Treatment. Isotype control MFI was always < 150. % of NT and statistically
significant difference calculated as in Table 4.
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Table 5
Effect of dexamethasone and trichostatin A on NKCA of NK92

Treatment

Lytic
Units

P
value

% NT

(compared to
NT)

No Treatment

P
value
(compared
to NT)

1202.24 
75

Lytic Units
P
value
(compared to
Dex)

0.0001

Dex (10-7 M)

655.97 
35

0.0001

51.51 
6.8

0.0001

TSA (100 nM)

1584.32 
95

0.003

133.5 
11.0

0.004

Dex (10-7 M) +
TSA (100 nM)

1205.44 
53

1.0

101.5 
8.2

0.998

0.0001

Data are mean values  S.E.M. N=7. Dex= dexamethasone. TSA= Trichostatin A. NT=
No Treatment. % of NT and statistically significant difference calculated as in Table 4.
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Supplement Table 1.
Additional Statistical Data for Table 3
For MFI

For % Change

Cellular
Protein

t

df

t

df

IFN gamma

5.052

5

11.023

7

TNF alpha

12.505

4

24.832

2

LFA-1

5.941

10

18.307

12

CD-2

-6.541

10

-10.663

5

Granzyme
B

2.716

10

4.207

11

NKp30

18.967

4

72.729

2

NKp46

-14.704

4.511

-16.584

3

Values are mean fluorescent intensity (MFI) of surface and intracellular proteins 
S.E.M., N= at least three independent experiments. Isotype control MFI was always <
150. % Change= (MFI No Treatment - MFI Dexamethasone)/(MFI No Treatment) X 100.
Statistically significant difference, No Treatment vs. Dexamethasone Treatment.
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Supplemental Table 2
Percent viability as determined by trypan blue staining

Treatment

No Treatment- 24 hours
No Treatment- 5 Days

Viability

86.6  1.1

93.9  0.8

Dex (10-7 M)- 24 hours

87.2  1.3

Dex (10-10 M)-5 Days

91.7 1.1

TSA (100 nM)

86.3  1.5

Dex (10-7 M) + TSA (100 nM)

84.7  0.8

Data are mean values  S.E.M. N=7. Dex= dexamethasone. TSA= Trichostatin A. NT=
No Treatment. Viability determined by: [(Number of living NK92 cells)/(total number of
NK92 cells)]*100
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Supplemental Table 3.
Flow cytometric and Immunofluorescent Antibody Dilutions

Antibodies SpecificityConjugate

PBMCs

NK92 cells

CD8-PerCP-Cy5.5

1:25

n/a

CD4-Pacific Blue

1:25

n/a

H4-K8-Ac-unconjugated

1:50

1:50

H3K9-Ac-Alexa 488

1:50

1:50

H3K4me3- unconjugated

1:50

1:50

60

1:100

1:100

Glucocorticoid Receptorunconjugated

n/a

1:10

MSK-1-phosphorylationunconjugated

n/a

1:100

Secondary IgG-FITC

Values are dilution factors for antibodies. n/a= not applicable

61

Specific Aim 2. Characterize the chromatin remodeling proteins associated with
global epigenetic patterns observed in NK92 cells treated with the glucocorticoid,
dexamethasone.

During psychosocial distress immune effector genes are differentially impacted
with subsets being up-regulated (pro-inflammatory cytokines) [7-9] and others down
regulated (lytic activity) ) [14, 15, 63, 105, 173]. GCs have been shown to mediate
immune dysregulation during psychosocial distress by altering global epigenetic patterns
[5]. However, the mechanism of how GCs impact global epigenetic patterns during
psychosocial distress remains unknown. In vitro analysis has shown that GCs can alter
global epigenetic patterns by interacting with chromatin remodeling proteins [49, 144146]. However, chromatin remodeling proteins have not been linked to immune
dysregulation during psychosocial distress. Therefore exploratory analysis of chromatin
remodeling protein cellular localization patterns during chronic GCs treatment would
advance understanding of molecular mechanisms of immune dysregulation.
Identification of chromatin remodeling proteins altered during psychosocial distress may
allow for better understanding of these GCs induced immune effects.

Chromatin Remodeling Protein Levels and Cellular Localization at Day 5:
GCs can alter global epigenetic patterns by interacting with chromatin remodeling
proteins such as HDACs and histone acetylases (HATs). Previous work has shown that
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GCs interact with HDAC1, HDAC2, HDAC3 and p300 [49, 143]. Flow cytometry was
used to determine intracellular total protein levels for Class I HDACs, HAT p300 and
glucocorticoid receptor (GR) at Day 5. Figure 8a shows the quantification of three
independent experiments measuring HDAC1, HDAC2, HDAC3, p300 and GR at Day 5.
Chronic Dex treated NK92 cells chromatin remodeling protein MFI is standardized to
untreated NK92 cells chromatin remodeling protein MFI (See Materials and Methods).
No change in total HDAC1, HDAC2, p300 and GR levels were measured at Day 5.
Significant reductions in HDAC3 levels were measured. (p<0.05, Figure 8a). A
representative FACs plot of total HDAC3 reductions is depicted in Figure 8b. The black
line depicts the total HDAC3 levels in untreated NK92 cells, which the dashed grey line
depicts the reduced total HDAC3 levels in chronic Dex treated NK92 cells.
Cellular localization of chromatin remodeling proteins of NK92 cells was
measured by immunofluorescent microscopy on the Amnis Image Stream X (Figure 9).
Basal cellular localization patterns varied between chromatin remodeling proteins, with
some proteins measured primarily nuclear (HDAC1, p300) localization, while others
were distributed into both the cytoplasm and the nucleus (HDAC2, HDAC3 and GR).
Regardless of cellular treatment, ~75% of NK92 cells followed these staining patterns.
The remaining ~25% was due to doublet staining or cells improperly imaged. Figure 9
depicts a representative image of untreated (Figure 9a) and chronic Dex treated (Figure
9b) NK92 cells stained for DAPI (nuclear stain),anti-HDAC2 (FITC) and anti-HDAC1
(APC). The chronic Dex treated image shows increased nuclear staining of HDAC2
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(Figure 9). Quantification of nuclear localization was determined by IDEAS nuclear
localization wizard software, allowing for measurement of nuclear localization for 1000
images per treatment. Increased nuclear localization of HDAC2 was measured at Day 5
in the chronic Dex treated NK92 cells when compared with the untreated cells (Figure
10).

Chromatin Remodeling Protein Levels and Cellular Localization at Day 2:
Slight decreases in intracellular perforin and granzyme B began at Day 2
(Supplemental Figure 1) therefore chromatin remodeling protein levels were assessed at
day 2. Flow cytometry was used to determine intracellular protein levels for Class I
HDACs, HAT p300 and GR at Day 2. Figure 11 shows the quantification of 3
independent experiments measuring HDAC1, HDAC2, HDAC3, p300 and GR at Day 2.
Chromatin remodeling protein levels (MFIs) of chronic Dex treated NK92 cells are
standardized to protein levels (MFIs) of untreated NK92 for each experiment (n=3). No
change in total HDAC1, HDAC2, HDAC3 p300 and GR levels were measured at Day 2
(Figure 11).

Phosphorylated Chromatin Remodeling Protein Levels at Day 2:
Chromatin remodeling protein cellular localization at Day 2 was assessed by flow
cytometry. Phosphorylation of chromatin remodeling proteins can be a marker for
enzymatic activity and nuclear localization [176]. Flow cytometry was used to determine
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intracellular phosphorylated protein levels and Figure 12 shows the quantification of 3
independent experiments measuring phosphorylated HDAC2 and phosphorylated MSK1. Chromatin remodeling protein levels (MFIs) of chronic Dex treated NK92 cells are
standardized to protein levels (MFIs) of untreated NK92 for each experiment (n=3).
Significant increases in HDAC2-p were measured at Day 2 in chronic Dex treated NK92
cells (Figure 12, p<0.05). No change in MSK-1-p was measured at Day 2 (Figure 12).
Increases in HDAC2-p at Day 2 suggest that translocation into the nucleus begins as early
as Day 2, with increased nuclear localization remaining at Day 5 (Figure 10).
Additionally, increases in HDAC2-p were measured at Day 5, corresponding with
increased HDAC2 nuclear localization.
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Specific Aim 3. Characterize the global epigenetic patterns and the intracellular
localization of chromatin remodeling proteins of the NK cells of women as they
respond to and recover from breast cancer diagnosis.

GCs, which are altered during the psychosocial distress of breast cancer diagnosis
[1-3], are known to impact epigenetic patterns [48, 128, 129]. Changes in epigenetic
patterns have been linked to changes in gene transcription. It is possible that the
mechanism mediating immune dysregulation during psychosocial distress is an
epigenetic mechanism. The global epigenetic patterns of women as they respond to and
recover from breast cancer were analyzed in order to understand whether epigenetic
mechanisms contribute to psychosocial distress mediated immune dysregulation.

Descriptive Characteristic of Participants:
Twenty-nine women were enrolled in the Cancer group and 27 women were
enrolled in the Control group. These women were enrolled and evaluated longitudinally
at 4 times (T1-T4, Figure 13). Demographics, disease and treatment characteristics of
participants are summarized in Table 6. Women were predominantly Caucasian in both
the Cancer (77.4%) and Control groups (70.4%). The majority of the women were
married in both the Cancer group (74.2%) and Control group (51.9%). The majority of
Cancer women had Stage 0 breast cancer (79.2%) and underwent a combination of
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surgery, radiation and hormonal treatment (54.2%). The majority of surgeries were
breast conserving lumpectomies (70.4%).

Psychological Assessment:
Psychological assessments administered to the Cancer and Control groups were the
Perceived Stress Scale (PSS), which measured general appraisal of stress, and the Centers
for Epidemiologic Studies-Depression (CES-D), which measured depressive mood.
Women in the Cancer group had increased PSS (Figure 14) and CES-D (Figure 15)
when compared to the Control group at cancer diagnosis (T1; p<0.01). Increases in
perceived stress persisted at T2 (p<0.01), T3 (p<0.05) and T4 (p<0.05) in the Cancer
group when compared to the Control group (Figure 14). Depressive mood levels of the
Cancer group returned to levels comparable to Control group at T2, T3 and T4 (Figure
15).

Natural Killer Cell Activity:
Increased PSS have been linked to alterations in NK cell function. The ability of
NK cells to lyse tumor cell targets was evaluated for the NK cells of the Cancer and
Control groups by measurement of NKCA. NKCA was significantly reduced in the
Cancer group at T1 when compared with the Control group at T4 (Figure 16, p<0.05).
Analysis of circulating NK cell percentage showed no difference between Cancer vs.
Control groups. Data not shown.
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IFN gamma Production:
Increases in PSS have also been associated with alterations in pro-inflammatory
cytokine production [7-9]. The ability of total peripheral blood mononuclear cells
(PBMCs) to produce IFN gamma after 48 hour stimulation was measured. Significant
increases in produced IFN gamma levels were measured in the Cancer group when
compared with the Control group (Figure 17) at T3 (p<0.05) and T4 (p<0.05). IFN
gamma was not detected in plasma of Cancer or Control groups.

Plasma IL-6:
Circulating interleukin-6 (IL-6) levels in the plasma were measured by ELISA.
Significant increased plasma IL-6 levels were observed in the Cancer group when
compared with the Control group at T2 (Figure 18, p<0.05).

Psychological, Immunologic and Epigenetic Analysis of Selected Groups of Women:
For immunologic and epigenetic analysis a selection technique (described in
Materials and Methods) was used to assess women at peak stress time periods. This
selection technique created three groups, Cancer Pre, Control and Cancer Post. Cancer
Pre women reported increased perceived stress and decreased NKCA prior to radiation
treatment when compared to the Control group.
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Psychological Assessment of Cancer Pre, Control and Cancer Post Groups:
Perceived stress and depressive mood were measured in selected groups (Cancer
Pre, Control and Cancer Post. The Cancer Pre group had increased PSS (Figure 19a)
when compared to the Control group (p<0.001) and Cancer Post Group (p<0.05) as
measured by ANOVA (F2,61=11.7, p=0.0001). The Cancer Pre group had increased CESD (Figure 19b) when compared to the Control group (p<0.001) and Cancer Post Group
(p<0.05) as measured by ANOVA (F2,62=9.9, p=0.0001).

Natural Killer Cell Activity of Cancer Pre, Control and Cancer Post Groups:
As NK cell are especially sensitive to alterations in psychosocial distress the
ability of NK cells to lyse tumor cell targets was evaluated in the Cancer Pre, Control,
and Cancer Post groups. NKCA was significantly reduced in the Cancer Pre group when
compared with both the Control group (Figure 20; p<0.05) and Cancer Post group
(Figure 20; p<0.05) as measured by ANOVA (F2,64=3.159, p=0.049). Analysis of
circulating NK cell percentages demonstrated no differences among Cancer Pre, Cancer
Post and Control groups (Figure 21a).

Intracellular IFN gamma of PBMCs of Cancer Pre, Control and Cancer Post Groups:
NK cells can lyse tumor cells and produce pro-inflammatory cytokines. PBMCs
intracellular IFN gamma levels following 4 hour stimulation with leukocyte activation
cocktail were measured by flow cytometry. In the Cancer Pre group, intracellular IFN
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gamma MFI of NK cells was numerically increased when compared with the Control
group (Figure 22; p<0.05) and Cancer Post group (Figure 22; p<0.05) and as measured
by ANOVA (F2,56=8.8, p=0.001). Increases in intracellular IFN gamma of NK cell
inversely correlated with NKCA (Table 7).
Increases in intracellular IFN gamma levels were not limited to the NK cell
population. In the Cancer Pre group intracellular IFN gamma MFI of CD4+ T helper
lymphocytes was numerically increased when compared with the Control group (Figure
23; p<0.05) and Cancer Post group (Figure 23; p<0.05) as measured by ANOVA
(F2,54=7.0, p=0.002). No differences in circulating CD4+ T helper lymphocyte
percentages were observed among Cancer Pre, Control and Cancer Post (Figure 21b).
No differences in intracellular IFN gamma levels were measured in CD8+ cytotoxic T
lymphocytes when comparing the Cancer Pre, Control and Cancer Post groups. Data not
shown.

Salivary Cortisol of Cancer Pre, Control and Cancer Post Groups:
Hypothalamic-pituitary-adrenocortical (HPA) axis activation produces a cascade
of neuroendocrine products that result in elevated circulating adrenal derived GCs, which
is cortisol in humans. Salivary cortisol was collected 5 times per day for 2 days prior to
phlebotomy. Salivary cortisol levels were measured by ELISA and diurnal cortisol
rhythms were determined. Cortisol waking rise has been shown to be altered in women
with breast cancer [59, 60, 177]. No significant differences in cortisol paratmeters were
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measured between the Cancer Pre and Control groups (Supplemental Table 8).
Relationships between cortisol waking rise and immunologic function were investigated.
Significant negative correlations were measured between salivary cortisol and NKCA
(Table 7, p<0.05) for Cancer Pre and Control groups combined. Additionally, significant
positive correlations were measured between cortisol waking rise and intracellular IFN
gamma of NK (Table 7, p<0.01) and CD4+ T helper lymphocytes (Table 7, p<0.01) for
Cancer Pre and Control groups combined. These data suggest that alterations in salivary
cortisol are associated with immunologic alterations observed in women.

Intracellular Perforin Levels in NK Cells of Cancer Pre, Control and Cancer Post
Groups:
NK cells produce their effects against tumor cells by first engaging the tumor
target, followed by exocytosis of NK cytolytic granule constituents, such as perforin,
leading to tumor cell lysis. Intracellular perforin levels in NK cells and cytotoxic T
lymphocytes were measured by flow cytometry. No differences were observed in
perforin levels in cytotoxic T lymphocytes between Cancer Pre (62.1 10), Control
(59.38) and Cancer Post (76.215) groups. Significant positive correlations were found
between NKCA and perforin levels in NK cells (Table 8; p<0.05). Relationships
between CD56 staining intensity and cytotoxic phenotypes of NK cells have been shown
previously [91, 92]. Therefore staining patterns between CD56 versus perforin were
analyzed by flow cytometry. The CD56-dim population stained positively for
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intracellular perforin (Figure 24). Representative FACS plots for a Cancer Pre and
Control woman are shown with the CD56-dim population noted in the box; this
represents ~90% of the NK cells which is consistent with previous findings [91, 92].
Additionally, ~90% of the NK cells in the Cancer Pre group also stained positive for
intracellular IFN gamma (Supplemental Figure 2). The representative flow histogram
depicted in Supplemental Figure 2 shows the typical intracellular IFN gamma staining
pattern for the Cancer Pre group with the majority (89.9%) of the NK cells staining
positively for intracellular IFN gamma. These cells had differential CD56 staining, with
both bright and dim CD56 cells producing IFN gamma. The same NK cells derived from
women with breast cancer stained positively for intracellular perforin as were able to
produce IFN gamma upon stimulation. These flow cytometric data identify a
dichotomous phenotype within the NK cells of the Cancer Pre women, with NK cells
exhibiting both decreased NK cell lytic activity (as measured by NKCA and intracellular
perforin) and increased intracellular IFN gamma.

Epigenetic Analysis of Cancer Pre, Control and Cancer Post Groups:
GCs enter cells by passive diffusion and bind to the intracellular GRs, activating
GR. Once activated, GR translocates into the nucleus and can lead to gene repression or
transcriptional activation by recruiting chromatin remodeling proteins and altering
epigenetic modifications, such as acetylation. Increases in acetylation are associated with
transactivation, while decreased acetylation results in gene repression [6, 121, 122, 129].
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Global H4-K8-Ac and H3-K9-Ac in NK cells was measured by flow cytometry. Global
H4-K8-Ac in NK cells positively correlated with NKCA (p<0.05) and intracellular
perforin levels (p<0.01) in NK cells (Table 8). No relationships with global H3-K9-Ac
and NKCA (Pearson r =0.326, p=0.328) or intracellular perforin (Pearson r=-0.397,
p=0.227) were found. These data suggest that global H4-K8-Ac alterations result in
altered NK cell activity in the Cancer Pre women. To investigate if decreased global H4K8-Ac patterns were measured in women with high perceived stress a median split was
performed on the Cancer Pre group and the Control groups, creating sub groups with
individuals with very high perceived stress (PSS mean=251.2) and very low perceived
stress (PSS mean=60.7). Global H4-K8-Ac in NK cells was assessed by flow cytometry
within these sub groups. Decreased global H4-K8-Ac in CD56+ NK cells for the Cancer
Pre, high PSS group was demonstrated when compared to the Control group, low PSS
(Figure 25; p<0.05). No significant difference was measured among groups for global
H3-K9-Ac groups (Figure 27). CD56 staining patterns did correspond with NK cell lytic
activity (CD56 dim v. perforin, Figure 24) and intracellular perforin correlated with
global H4-K8-Ac (Table 8). Therefore, sub populations of H4-K8-Ac levels relative to
CD56 were investigated to determine if H4-K8-Ac stained brighter in CD56 dim
populations. Staining patterns between CD56 v. H4K8-Ac were investigated by flow
cytometry. Representative FACS plots depicted in Figure 26 show uniform staining
patterns for both Cancer Pre and Control groups with no H4-K8-Ac sub populations
identified, thus H4-K8-Ac did not stain relative to CD56 staining.
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To investigate if changes in global histone acetylation patterns were specific to
NK cell lytic activity relationships between global histone acetylation patterns and CD8+
T lymphocytes were also investigated. CD8+ T lymphocytes have been shown to lyse
target cells; by first adhering to the cell, followed by granule release of perforin and
granzymes leading to apoptosis of the target cell. No relationships were measured
between global H4-K8-Ac and intracellular perforin in CD8+ T lymphocytes (Pearson
r=0.252, p=0.121). Relationships between H3-K9-Ac and intracellular perforin levels
remain to be determined.

Chromatin Remodeling Proteins Levels of Cancer Pre, Control and Cancer Post Groups:
Activation of the HPA axis by psychosocial distress releases GCs. GCs can alter
global epigenetic patterns by interacting with chromatin remodeling proteins such as
HDACs. Significant inverse correlations were measured between cortisol awakening rise
and NKCA suggesting that GCs were impacting NK cell lytic function (Table 7). These
reductions in NKCA also significantly correlated with decreases in global H4-K8-Ac
levels in NK cells of the Cancer Pre group. HDAC levels in NK cells were investigated
by flow cytometry. Class I HDAC levels and cellular localization patterns were altered
in in vitro analysis (Figure 9, 10, 12) therefore HDAC1, HDAC2 and HDAC3 were
analyzed in the NK cells of the Cancer Pre and Control groups. Exploratory analysis on a
subset of Cancer Pre women found increased phosphorylated HDAC2 (HDAC2-p) in the
NK cells of women with increased PSS (Figure 28). Phosphorylation of HDAC2 is a
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marker of nuclear localization and enzymatic activity [176]. No relationships were found
with HDAC1 or HDAC3. Due to limited cell numbers, immunofluorescence microscopy
was not performed.
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Table 6
Demographics characteristics.
Cancer

Control

(N=29)

(N=27)

Age (years) mean  SD

57.4  9.0

56.2  9.0

BMI

26.2  8.6*

21.7  8.0

Frequency

Frequency

Caucasian

23

19

African American

3

3

Hispanic

2

1

PI/Asian

1

4

Marital Statusa
Married

23

14

1

6

2

4

Race

Divorced/separated
Single

99

Widowed

Incomea
10,000-29,000
30,000-59,000
60,000 and higher

2

1

1

2

7

3

17

21

100

Stage of Cancera
Stage 0
Stage I
Stage IIA

Treatmenta
Surgery only
Surgery + radiation therapy
Surgery + hormonal therapy
Surgery + radiation therapy +
hormonal therapy

Surgery Typea
Breast conserving

19
5
0

6
3
2
13

19
8

Mastectomy
SD= standard deviation. a=missing data for some women in cohort; answers were
omitted and no imputation technique was used for missing data. *p=0.05, p value for
Cancer v. Control. BMI= Body Mass Index
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Table 7
Correlations for Cancer Pre and Control Groups Combined (a).

Salivary
Cortisol

NKCACD56+
NK cells

Intracellular
IFN gamma
of CD56+
NK cells

Intracellular IFN
gamma of CD4+
T lymphocytes

Salivary
Cortisol
Waking Rise

1

-0.311*

0.426**

0.431**

NKCACD56+ NK
cells

-0.311*

1

-0.370*

Intracellular
IFN gamma
of CD56+
NK cells

0.426**

-0.370*

1

0.849**

Intracellular
IFN gamma
of CD4+ T
lymphocytes

0.431**

0.849**

1

Values are Pearson r value, n=44 for Cancer Pre and Control groups combined. Cancer
Pre (Cancer women with increased PSS and decreased NKCA prior to radiation
treatment); Control (decreased PSS and increased NKCA) See Materials and Methods for
full description. *p<0.05, ** p<0.01. Cancer Pre n= 24, Control n= 20.
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Table 8
Correlations for Cancer Pre and Control Groups Combined (b).

NKCA

Perforin MFI of
NK cells

Global H4K8-Ac of NK
cells

NKCA

1

0.358*

0.298*

Perforin MFI of NK
cells

0.358*

1

0.441**

Global H4-K8-Ac of
NK cells

0.298*

0.441**

1

Values are Pearson r value, n=44 for Cancer Pre and Control groups combined.
Cancer Pre (Cancer women with increased PSS and decreased NKCA prior to
radiation treatment); Control (decreased PSS and increased NKCA) See Materials
and Methods for full description. *p<0.05, ** p<0.01. Cancer Pre n= 24, Control n=
20.
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Supplemental Table 4.
Surgery Effects on Cancer Women at T2.

Breast
Conserving
Lumpectomy Mastectomy

n
p value

n

Breast
Masectomy
Conserving

PSS

17.3  2.5

20.7  3.5

0.467

15

6

CES-D

10.8  3.0

12.5  3.3

0.745

15

6

NKCA

87.0  18.4

94.4  37.1

0.841

15

7

IFN
gamma- NK
cells

0.31  0.04

0.28  0.06

0.724

15

7

Data are mean values  S.E.M. p value for Breast Conserving lumpectomy v.
Mastectomy.
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Supplemental Table 5.
Radiation Treatment Effects on Cancer Women at T3.

Radiation
Treatment

No Radiation
Treatment

PSS

15.7  2.7

CES-D

NKCA

IFN gammaNK cells

n

n

p value

Radiation

No
Radiation

14.7  3.0

0.788

9

6

12.9  4.8

9.7  4.7

0.655

9

6

140.7 
32.7

81.0  38.3

0.261

9

6

0.22  0.03

0.529

6

7

0.20 
0.02

Data are mean values  S.E.M. p value for Radiation Treatment v. No Radiation
Treatment.
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Supplemental Table 6.
IL-6 levels in Cancer Pre and Control groups.

Cancer Pre

Control

n

n

p value

Cancer
Pre

Control

Produced IL6 Fold
Increase

989.7 
479.2

172.18 
114.0

0.115

17

15

Percent IL6+ of CD14+
monocytes

11.0  1.3

6.6  1.4

0.039

17

16

Data are mean values  S.E.M. p value for Cancer Pre v. Control. Cancer Pre
(Cancer women with increased PSS and decreased NKCA prior to radiation
treatment); Control (decreased PSS and increased NKCA) See Materials and
Methods for full description.

106

Supplemental Table 7.
Selection Criteria.

Time
point
selected

PSS-T1

NKCA-T1

PSS-T2

NKCAT2

004

13

4

13

7

1

006

24

30

16

26

1

009

27

79

34

59

2

10

19

146

17

192

1

11

18

45

31

78

2

12

20

133

20

75

2

15

21

52

17

157

1

17

6

7

8

24

2

107

18

21

74

19

132

1

19

23

110

13

44

1

22

n/a

69

28

92

2

23

24

205

25

130

2

26

7

41

6

33

2

29

24

104

13

103

1

For other data selected missing psychological or immune data determined selection.
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Supplemental Table 8.
Other Cortisol Parameters

Cancer Pre

Control

p value

Awakening

0.44  0.16

0.420.11

0.942

~30 minutes after
awakening

0.450.05

0.360.03

0.237

0.160.04

0.09.01

0.203

0.100.03

0.070.01

0.447

0.090.05

0.060.01

0.622

1.450.23

1.330.20

0.732

Noon

5 pm

Bedtime

Area Under the Curve

Data are mean values  S.E.M. p value for Cancer Pre v. Control. Cancer Pre
(Cancer women with increased PSS and decreased NKCA prior to radiation
treatment); Control (decreased PSS and increased NKCA) See Materials and Methods
for full description.

CHAPTER 7
DISCUSSION
The data presented herein identifies global histone 4 lysine 8 acetylation (H4-K8Ac) as an epigenetic modification associated with NK cell lytic function. Additionally,
HDAC2 was identified as a potential regulator of global H4-K8-Ac in NK cells. The
discussion section is divided by treatment systems (short-term, high dose dexamethasone
(Dex) treatment of NK92 cells, chronic Dex treatment of NK92 cells and ex vivo analysis
of peripheral blood mononuclear cells (PBMCs) derived from women with breast
cancer). In vitro Dex treatment systems results will be discussed independently, before a
brief comparison of the two systems (Specific Aim 1 and Specific Aim 2). Ex vivo
analysis of PBMCs cells derived from women with breast cancer focuses on
psychological, immune and epigenetic analysis of Cancer Pre, Control and Cancer Post,
as this selected grouping systems identifies a population of women with increased
psychosocial distress (Specific Aim 3). Finally, the discussion section ends with a
comparison of the in vitro and ex vivo systems.

Short-Term, High Dose, Dex Treatment of NK92 Cells:

Therapeutic doses of glucocorticoids (GCs) depress the level of NK cell activity
(NKCA) in the peripheral blood of treated individuals [178] and physiological
concentrations of GCs suppress NKCA of PBMCs [4-6]. This inhibition of NKCA is time
109
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and dose dependent [4]. In the short-term, high dose, Dex treatment system similar
concentrations and length of exposure of Dex were used as was assessed in Holbrook et
al. It is well-established that acute stress is associated with a reduction in NK cell
functional activity [64, 179, 180], which may be mediated by increased adrenergic
activity [181], as well as by the GC hormone, cortisol [182]. This investigation focused
on the effects of short-term, high dose treatments with the synthetic GC, Dex, on the
cellular function of the human NK cell line, NK92. The findings demonstrate reductions
in; NKCA, granule constituents, adhesion to tumor targets and interferon gamma (IFN
gamma) production. Each of these reductions was associated with reduced global
acetylation of histone 4 lysine 8 (H4-K8-Ac). Global reductions in H4-K8-Ac associated
with Dex treatment suggests that global acetylation patterns may reflects H4-K8-Ac
patterns at promoter regions of NK cell effector genes (i.e. perforin and granzyme B).
This was shown to be the case as reductions in global H4-K8-Ac were associated with
decreased H4-K8-Ac at the proximal promoter regions of perforin and granzyme B
genes, with concomitant reduction in gene transcription [6].

It is well known that GCs can induce gene transcription, yet their major effect on
the immune system is to suppress transcription. The number of immune response genes
regulated by GCs is conservatively estimated at more than 1000 [45, 183-185]. GCs can
decrease cytokine, chemokine, and receptor expression by PBMCs [186]. These effects
are primarily due to the GC action at the transcriptional level. Although activated
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glucocorticoid receptors (GR) can directly interact with pro-inflammatory transcription
factors like AP-1 (Fos-Jun heterodimers) and NFk-B (p65-p50 heterodimers) [187-189],
the primary effect of GCs are downstream of transcription factor binding to DNA with
gene repression a consequence of the reversal of histone acetylation [48, 190]. Activated
GR repress gene expression by direct inhibition of histone acetyl transferase (HAT)
activity and by active recruitment of histone deacetylase (HDAC) complexes [48]. Most
importantly, physiologically elevated GC levels induce HDAC expression in a time and
dose dependent manner [48] resulting in deacetylation of histones, increased tightening of
DNA, and reduced expression of immune response genes [191]. Moreover, the effect of
GCs on chromatin structure and on immune response genes is reversible with HDAC
inhibitors (HDACi) [131-133]. By repressing a downstream target of transcription factor
activation (chromatin accessibility), GCs reduce gene expression irrespective of the exact
transcription factor requirement for an individual gene. Hence, the data presented herein
suggest that one likely explanation for the GC induced reduction in NKCA and in IFN
gamma production is decreased transcription of immune effector genes due to reduced
proximal promoter accessibility.

The results presented herein demonstrate the effect of short-term, high dose Dex
in this human NK cell line. Further, Dex at the examined concentration and period of
treatment profoundly reduced the degree of H4-K8 acetylation as judged by western blot
analysis. Such a global effect of this GC suggests a profound reduction in overall
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functional NK cell activity. In actuality, reductions in functional activity, although
significant, approximated 50%. This was true for NKCA, for cytokine production and for
the accessibility of the promoters IFN gamma, perforin and granzyme B [6]. This
observation suggests that other effects in addition to transrepression may be ongoing as
well and may influence the outcome of short-term, high dose Dex treatment and its
impact on immune function. Additionally, treatment of NK92 cells with an HDACi
(TSA) increased both global H4-K8-Ac, NKCA and IFN gamma levels in the presence of
short-term, high dose Dex concentrations. These data suggest that global acetylation
changes mediated by alterations in HDACs are implicated in altered NK cell lytic
function. No differences in global H4-K8-Ac MFI were measured when NK92 cells were
treated with TSA alone when compared to untreated cells (Table 3). TSA alone did
significantly increase NKCA and IFN gamma levels when compared to untreated cells
(Table 4 and 5). Since TSA inhibits all classes of HDACs it’s possible that treatment of
NK92 cells with TSA alone causes increases in acetylation of other histone residues
resulting in increased NKCA and IFN gamma production. Investigation into other
histone residue acetylation status is assessed below in ex vivo analysis of NK cells
derived from women with breast cancer. TSA inhibits all classes of HDACs, therefore
although treatment with Dex and TSA suggests that global H4-K8-Ac and NK cell
functional changes are a result of HDACs it did not answer the question as to which
HDAC is inhibited. Currently, there are not any HDAC specific inhibitors available, thus
no further HDACis were investigated.
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In contrast to the results described herein, previous work has shown that HDACi
(valproic acid and suberoylanilide hydroxamic acid) reduce the cytotoxic activity of NK
cells [192]. NK cell inhibitory effects of HDACi were associated with reduced surface
expression and function of specific activating receptors (NKp46 and NKp30) responsible
for the induction of NK cell-mediated cytotoxicity. This inhibitory effect was at the
transcriptional level as judged by real time PCR. These effects were only seen with IL-2
activated NK cells, with no effect on fresh NK. No effect of these HDACi was observed
for LFA-1 or for IL-2 receptors. Surface expression levels of inhibitory receptors
including KIR and NKG2A were not influenced by HDACi treatment, indicating a
specific effect of HDACi on NK cell activating receptors. These differences, with regard
to the results of this study, may be explained in multiple ways. The likely difference is
that TSA reversed the effect of dexamethasone within a one to six hour period, while the
effects of valproic acid and suberoylanilide hydroxamic acid were observed in NK cells
cultured for 4 days with the HDACi.

The effect of short-term, high dose Dex treatment on NK92 cells was not limited
to NKCA and IFN gamma. Quantitative reductions were also demonstrated for the
lymphocyte adhesion molecule, LFA-1, which is known to mediate binding of NK92
cells to K562 [174], as well as the essential granule constituents, perforin and granzyme
B [175]. These quantitative reductions were not universal in that the adhesion molecule,
CD2 (also know to mediate binding of NK92 cells to K562) [174, 175] was not affected.
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In sum, these results associate short-term, high dose Dex treatment induced
epigenetic histone modification with NK cell function. The acetylation status of H4-K8
was found to correspond with NKCA, an adhesion molecule known to mediate the
interaction of NK with tumor cells and granule constituents. The function of NK cells
against tumor cells is carried out first by engagement of the tumor target, followed by
exocytosis of NK cytolytic granule content and/or production of immune effector
cytokines. Short-term, high dose Dex treatment of NK92 cells also resulted in decreased
pro-inflammatory cytokine intracellular and produced levels (IFN gamma). The
observation reported herein, demonstrate the effect of short-term, high dose Dex
treatment to be at the epigenetic level with reduced transcription of immune effector gene
products required for optimal functional activity of NK cells, leading to a reduction in
NK cell functional activity. Further it may be that dose and time of treatment as
described herein approximate the effect of short term or acute physiological effects of
this GC and that greater dose and/or more prolonged treatment may reveal a more
profound outcome and was explored next.

Chronic Dex Treatment of NK92 Cells:

This investigation focused on the effects of increased time, but decreased
concentrations of Dex on functional activity of NK92 cells. Treatment of NK92 cells
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with high dose Dex (10-7) for longer than 24 hours resulted in reduced viability. Thus,
decreased concentrations of Dex (10-10) were used to assess increased exposure of NK92
cells to Dex treatment. The findings demonstrate reductions in; NKCA and granule
constituents (perforin and granzyme B). Interestingly, these decreases in NK cell lytic
activity were associated with increased IFN gamma production, resulting in a
dichotomous NK cell phenotype. Reductions in NKCA, perforin and granzyme B were
associated with reduced global acetylation of H4-K8-Ac.

GCs impact global acetylation patterns through recruitment of chromatin
remodeling proteins. GCs enter cells by passive diffusion and bind to the ubiquitously
expressed intracellular GRs. After a GC binds to GR, ligand activated GR is translocated
to the nucleus. In the nucleus activated GR regulates the transactivation or
transrepression of GC-responsive genes [193]. Ligand activated GR has also been shown
to impact gene expression through interaction with other chromatin remodeling
complexes such as HATs and HDACs. In the data presented herein GR induced
alterations of class I HDACs (HDAC1, HDAC2, HDAC3) were investigated. Class I
HDACs were chosen because previous work has found class I HDACs can interact with
GR [49-51] and also alterations in class I HDAC function can impact NK cell lytic
activity [141]. In the chronic Dex treatment of NK92 cells, increased nuclear localization
of HDAC2 corresponded with decreased global H4-K8-Ac and decreased NKCA
(Figures 7, 9, 10 and 12 ). Increased HDAC2 nuclear localization was measured by
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immunofluorescence and flow cytometric analysis of increased phosphorylation of
HDAC2 (HDAC2-p), which serves as a nuclear localization signal [176]. Increased
HDAC2-p was measured at Day 2 (Figure 12), with nuclear localization of HDAC2
persistent at Day 5 (Figure 10). These data suggest that HDAC2 nuclear localization
associated with decreased global acetylation of H4-K8. Additionally, time course
analysis suggests that this occurs rapidly, beginning as early as Day 2 of the treatment.
Analysis of HDAC1 measured no changes in total protein levels, whereas measurement
of HDAC3 revealed significant decreases to total protein level, suggesting that it is
HDAC2 responsible for these global decreases in H4-K8-Ac. Analysis of other classes of
HDACs will need to be done to confirm that HDAC2 alone is responsible for global
changes in H4-K8-Ac.

Cellular localization patterns of GR were investigated in chronic Dex treated
NK92 cells. Analysis of GR revealed no differences in total protein or cellular
localization of GR when comparing chronic Dex treated NK92 cells and untreated NK92
cells [194]. GR cellular localization patterns may not have been observed due to the
natural cyclic activity of GR, continuous cycling in and out of the nucleus [195-197].
Studies have shown that GR rapidly translocates in and out of the nucleus during normal
cellular processes, making measurement of GR co-localization and nuclear localization
difficult.
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Alterations in global histone acetylation patterns can be mediated by GCs
interaction with HATs [136, 137]. As a result cellular levels of p300, a HAT known to
interact with GR, were investigated in chronic Dex treatment of NK92 cells. No changes
in total p300 levels were measured throughout the chronic Dex treatment (Figures 8 and
11). Additionally, p300 localized primarily to the nucleus in chronic Dex treatments. No
relationships between p300 total levels or cellular localization and global H4-K8-Ac were
identified. Analysis of other HATs remains to be determined.

In sum, these results presented herein found chronic Dex treatment caused a
dichotomous NK cell phenotype, characterized by decreased NKCA and increased
intracellular IFN gamma. Additionally the global acetylation status of H4-K8 was found
to correspond with decreased NKCA. The observation reported herein, demonstrate the
effect of chronic Dex treatment to be at the epigenetic level with reduced transcription of
NK cell lytic gene products that are required for optimal NCKA.

Comparison of Short-Term, High Dose and Chronic Dex Treatment Systems:

The effect of psychosocial distress on NK cell function has been, in large part,
attributed to elevations in GCs produced by stress-induced activation of the
hypothalamic-pituitary-adrenocortical (HPA) axis [1-3]. GCs have been shown to impact
gene expression through interactions with chromatin remodeling proteins, such as
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HDACs and HATs. Due to limited human sample numbers, in vitro systems to study the
effects of GCs on NK cell function were established. The effects Dex on the cellular and
molecular function of the human NK cell line, NK92 were used. Two in vitro systems
were developed; a short term, high dose Dex treatment system and a chronic Dex
treatment system. Both systems measured dramatic NK cell functional changes
following Dex treatment. Additionally, both short-term, high dose Dex treatment and
chronic Dex treatment of NK92 cells revealed the novel contribution that GCs can alter
the epigenome which mediate alterations in NK cell function.

In both the short term, high dose Dex treatment system and the chronic Dex
treatment systems significant decreases in NK cell lytic activity as determined by NKCA
and intracellular levels of granule constituents (perforin and granzyme B) were found.
This is consistent with previously published results that NKCA is especially responsive to
alterations in GCs [15, 63, 105]. Additionally, global decreases in H4-K8-Ac were
associated with decreased NKCA for both treatment systems suggesting that GCs alter
NKCA through alterations in this epigenetic modification. Interestingly, with short-term,
high dose Dex treatment, IFN gamma levels were decreased; whereas with chronic Dex
treatment, IFN gamma levels were increased. These opposite results suggest that proinflammatory cytokine regulation by Dex is highly dependent on dose and duration of
GC exposure. Interestingly, these varied results could explain discrepancies in the
literature in regard to psychosocial distress and pro-inflammatory cytokines, where some
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studies have measured increased pro-inflammatory cytokine levels and others measured
decreased pro-inflammatory cytokine levels [5, 7-9, 74, 75]. In those studies where
decreased pro-inflammatory cytokines were found, extreme increases in GCs may have
resulted in decreased pro-inflammatory phenotype. In studies where increased proinflammatory cytokines were found (as is in Specific Aim 3), moderate levels of GC
levels may be the cause. This theory is further supported by the fact that GCs have been
shown to be both immunosuppressive and immune-enhancing [9]. Development of these
two in vitro systems allowed for analysis of global epigenetic modifications associated
with altered NK cell function. Additionally, comparison of the two systems allowed for a
comparison of how dose and duration of GCs can impact NK cells.

Ex Vivo Analysis of Peripheral Blood Mononuclear Cells (PBMCs) Derived from Women
with Breast Cancer:

It is well-established that the diagnosis of breast cancer has emotional
consequences characterized by increased perceived stress, increased depressive mood and
increased anxiety. Several studies have shown that these emotional consequences [22],
termed in this dissertation as psychosocial distress, can lead to alterations in immune cell
function [5, 13-15]. NK cells are highly sensitive to increases in psychosocial distress
[15, 63, 105], with NKCA inversely correlating with perceived stress [107]. NK cell
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dysregulation is significant in that NK cells contribute to host protection from cancer
[102, 103, 198, 199] and NK cell activity has been correlated to increased survival in
women with metastatic breast cancer [109-114]. Hence, the psychological response to a
diagnosis of breast cancer diagnosis has clear biological consequence for women with
breast cancer, as it may negatively impact their prognosis.

This investigation focused on the effects psychosocial distress on functional
activity of NK cells with the hypothesis that global epigenetic patterns reflect a molecular
epigenetic mechanism by which immune function was altered. This study identified a
dichotomous phenotype in the NK cells of women with breast cancer, demonstrating
decreased lytic activity and increased intracellular IFN gamma. Additionally, global
acetylation of H4-K8-Ac was identified as an epigenetic modification which correlated
with NK cell lytic activity and intracellular perforin. Exploratory analysis identified
HDAC2 as a potential factor contributing to decreased global H4-K8-Ac and NKCA in
women experiencing psychosocial distress. Women with breast cancer (Cancer Pre=prior
to radiation treatment, See Materials and Methods) had increased PSS and decreased
NKCA. These decreases in NKCA positively correlated with both reduced cytoplasmic
perforin and global nuclear H4-K8-Ac. Additionally, in women with breast cancer who
reported extremely high PSS, there was a significant reduction in global H4-K8-Ac when
compared to Control women who reported low PSS (Figure 25). It is interesting to note
that although H4-K8-Ac changes were observed globally, acetylation changes of other

121

histone residues were not observed, specifically no changes were observed at histone 3
lysine 9 (H3-K9) acetylation (Figure 27). This is of note as other studies have found
relationships between H3-K9-Ac and granule components [126]. However in these
studies, H3-K9-Ac was investigated in promoter regions of granule component genes
(e.g. perforin and granzyme B), therefore H4-K8-Ac may serve as a better global marker
of altered NK cell function. Investigation into H3-K9-Ac in the promoter regions of
granule component genes has not yet been determined. These findings suggest that
global acetylation alterations at H4-K8 were residue specific, suggesting that H4-K8-Ac
serves as an epigenetic marker for NK cell lytic function. Analysis of global H4-K8-Ac
in other immune cell populations did not measure relationships between acetylation status
and function. No relationships between global H4-K8-Ac and intracellular perforin and
granzyme B in CD8+ T lymphocytes were measured. These data suggest that global H4K8-Ac patterns relate to alterations in NK lytic function, but not lytic function of CD8+ T
lymphocytes.

The results presented herein demonstrate that the women with breast cancer prior
to radiation treatment (Cancer Pre) have increased perceived stress as measured by a selfreport questionnaire (perceived stress scale, PSS). During periods of increased perceived
stress, activation of the HPA results in elevated circulating adrenal derived GCs,
primarily cortisol. Salivary cortisol levels, which correlates with plasma cortisol levels
[200, 201], was collected to determine diurnal cortisol rhythms in the Cancer Pre, Control
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and Cancer Post groups. Cortisol rhythms are characterized by an initial spike
approximately 30 minutes after waking, this initial spike it termed the cortisol awakening
rise (CAR). GC levels then gradually subside throughout the course of the day, reaching
a minimal level in the evening, just prior to bedtime. Increases in PSS in the Cancer Pre
group corresponded with decreased NK cell lytic function as measured by NKCA when
compared with both the Control and Cancer Post groups. These decreases in NKCA
negatively correlate with salivary CAR, thus women with lower NK cell lytic activity
have higher salivary CAR. This increase in CAR, may indicate that immune cells were
exposed to higher levels of cortisol for prolonged periods during the day. Repeated
exposure of NK cells to increased CAR may have allowed immune cells to be
epigenetically primed for immune dysregulation. Other cortisol parameters still need to
be assessed. However, CAR has been shown to be related to increased HPA activation
[55, 56]. Additionally, HPA activation has been shown to be associated with increased
psychosocial distress [57], suggesting that CAR was the appropriate cortisol parameter to
assess. These correlations between NKCA and CAR suggest that women with increased
PSS (Cancer Pre) have decreased NKCA as a result of increased NK cell exposure to
cortisol. In contrast, NK cells of women with decreased cortisol waking rise (Control)
may have been exposed to lower cortisol levels resulting in increased NKCA. Further,
since NKCA positively correlates with global H4-K8-Ac, cortisol may impact gene
transcription through recruitment of HDACs, leading to decreased histone acetylation.
Exploratory analysis of NK cells derived from women with breast cancer investigated
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relationships between HDAC2-p and global H4-K8-AC. HDAC2-p is a marker of both
nuclear localization and enzymatic activity [176]. Breast cancer women with increased
PSS and decreased global H4-K8-Ac also had increased nuclear HDAC2-p. These
finding are the first to identify HDAC2 as a potential mediator of decreased global H4K8-Ac and decreased NK cell lytic activity measured during periods of psychosocial
distress. Additional analysis to confirm these results is necessary.

Salivary cortisol levels, however, were not related to PSS scores and there are
several possible reasons for this. As enrollment numbers were low, the study at this time
may be under powered to measure these relationships. Additionally, in the majority of
the women, a positive waking rise was measured, however, a small percentage of women
had a negative waking rise. This could be due to improper salivary collection or could be
an individual specific phenotype characterized by a negative waking rise or a blunted
cortisol response which has been reported previously in women with breast cancer [59,
60]. At this time not enough women with negative waking rises to evaluate this group
independently, but would be interesting to investigate this as total sample size increases.
Finally, several different polymorphisms have been identified in the human GR gene, the
cognate receptor for GCs. GR is comprised of three domains; the amino-terminal
transactivating domain, the DNA binding domain and the carboxy-terminal ligand
binding domain [202]. The three most characterized polymorphisms are ER22/23K,
N363S and BcII. ER22/23K is an amino acid alteration from an arginine to a lysine and
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N363S is an amino acid switch from an aspragine to a serine, both of these
polymorphisms are located in the amino-terminal transactivating domain [203, 204].
BcII identifies a DNA switch from a cytosine to a guanine located in the linker region
between the transactivating domain and the DNA binding domain. All three of these GR
polymorphisms are associated with altered GC sensitivity. Characterization the GR
sequence and the number(s) of polymorphisms observed in the women with breast cancer
may identify a population of women more or less susceptible to fluctuates in cortisol.
This would allow for further investigations into relationships between PSS and salivary
cortisol within the population of breast cancer women most susceptible to alterations in
cortisol rhythm.

The effect of surgery or radiation treatment on psychological analysis and
immune function measured herein was investigated. Studies have shown that an interval
of 10-12 days after surgery provided ample time for surgical or anesthesia-induced
effects to dissipate [110, 153-162]. Nevertheless, type of surgery was investigated for
impact on both psychological states and immune function in the total Cancer group. The
majority of the women enrolled in the study were treated with breast conserving
lumpectomy with a small number of women treated with mastectomy (Table 6 and
Supplemental Table 4). No differences in perceived stress and depressive mood were
measured when comparing the women that underwent breast conserving lumpectomy
versus women that underwent mastectomy at T2 (Supplemental Table 4). Differences
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were investigated at T2 as this was the time point immediately following surgery (Figure
13). Additionally, when immune functions were analyzed no differences were measured
in NKCA and intracellular IFN gamma levels in the NK cells when comparing the
women that underwent breast conserving lumpectomy versus women that underwent
mastectomy (Supplemental Table 4). Radiation treatment effects were also investigated
in the Cancer group at T3 (Supplemental Table 5). Psychological and immunological
analysis did not occur during radiation treatment, however the closest time point, T3,
occurred 6-8 weeks following the completion of radiation treatment. The majority of the
women enrolled in the study were treated with radiation (Table 6), with a small
percentage undergoing surgery alone or surgery plus hormonal treatment. No differences
in perceived stress, depressive mood, NKCA or intracellular IFN gamma levels of the
NK cells were measured when comparing women that received radiation treatment and
those that did not (Supplemental Table 5). These data suggest that neither surgery nor
radiation treatment impacted psychosocial distress and immune dysregulation.

Perceived stress was not the only determinant of psychosocial distress associated
with the diagnosis of breast cancer; increases in depressive mood (CES-D) were also
measured. However, analysis of relationships between depressive mood, immune
function and epigenetic modifications revealed no relationships among these parameters.
PSS is a measure of global stress appraisal over the previous month, where as CES-D
assesses depressive mood for the previous week. Additionally, when analyzing PSS and
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CES-D within all the total groups, PSS was significantly elevated in the Cancer group at
T1 and T2 (Figure 14), however CES-D was only significantly elevated at T1 (Figure
15). Therefore PSS may better capture alterations in psychosocial distress experienced
by the women with breast cancer over a period of a month. Additionally, these brief
alterations in depressive mood may more accurately depict a temporary change in mood
state not indicative of chronic depression. Interestingly, previous studies have reported
dichotomous immune phenotypes in individuals with chronic depression [205]. This
reported immune phenotype was characterized by decreased NKCA and increased proinflammatory cytokines, specifically IL-6, IL-1 and TNF alpha. Unlike data presented
herein, this phenotype in chronic depression was not measured within a single immune
cell population (e.g. NK cells). Additionally, in chronic depression this dichotomous
phenotype was not predicted to be controlled by a single biological hormone (e.g.
cortisol). Thus, unlike previous reports the data presented herein suggest the novel
contribution that cortisol awakening response is associated with a dichotomous
phenotype in NK cells in women with breast cancer. Analysis of immune cell function
and epigenetic modifications within the total Cancer and total Control groups found no
relationships. This is likely due to the varied perceived stress trajectories of the Cancer
group. Additionally, several of the Control women recruited reported high perceived
stress making differences between global H4-K8-Ac in the total Cancer versus Control
groups difficult to discern. Due to these reasons, immune, cortisol, epigenetic and
chromatin remodeling protein analysis was performed on the selected groups (described
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in Materials and Methods section). Final conclusions await completion of the full study
as these resulted are highly limited due to inadequate power.

NK cells derived from women with breast cancer (Cancer Pre group) had
demonstrably increased intracellular IFN gamma levels when compared to IFN gamma
levels in NK cells of the Control group (Figure 22). In women with breast cancer IFN
gamma levels negatively correlated with NKCA, which strong implies a dichotomous
phenotype in the NK cells of women experiencing psychosocial distress. Additionally,
~90% of the CD56+ cells exhibited both intracellular IFN gamma (Supplemental Figure
2) and intracellular perforin (Figure 24), further implying that the same population of NK
cells exhibited reduced tumor cell lysis and increased production of IFN gamma.
Investigation into relationships between cortisol awaking rise (CAR) and intracellular
IFN gamma in NK cells did measure significant positive correlations (Table 7).
Additionally, CAR inversely correlated with NKCA (Table 7). These data suggest that
cortisol induced the increases in intracellular IFN gamma and decreases in lytic activity
in NK cells. Increases in intracellular IFN gamma levels were not limited to NK cells,
these increases were also measured in CD4+ T lymphocytes (T helper lymphocytes).
Additionally, significant positive correlations were measured between CAR and
intracellular IFN gamma in T helper lymphocytes (Table 7).

Relationships between intracellular IFN gamma levels and epigenetic
modifications were investigated; however significant correlations were not measured. No
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relationships were measured between global H4-K8-Ac and IFN gamma, further
suggesting that acetylation at this histone residue is responsible for altered NK cell lytic
activity. In NK cells, intracellular IFN gamma levels related to histone 3 serine 10
phosphorylation (H3-S10-P) (Pearson r =0.248, p=0.15, df=35), whereas in T helper
lymphocytes IFN gamma levels related to H3-K9-Ac (Pearson r=0.33, p=0.125, df=23).
These data suggest that cortisol may produce these effects on IFN gamma through
alteration in modifications of the tail of H3. This preliminary analysis corresponds with
previous work in the field. Other studies have shown relationships between acetylation
of H3 relating to IFN gamma in CD4+ T lymphocytes [125]. Those studies measured
acetylation of H3 at the IFN gamma promoter regions. Therefore continued analysis of
IFN gamma in CD4+ T lymphocytes and global H3-K9-Ac could find the novel
contribution of relating a global modification to pro-inflammatory cytokine production.
Further analysis to confirm these results is necessary.

IFN gamma was not the only pro-inflammatory cytokine measured in the ex vivo
analysis of NK cells derived from women with breast cancer. Tumor necrosis factor
alpha (TNF alpha) and interleukin-6 (IL-6) were also measured. No differences were
measured in NK intracellular or produced TNF alpha levels. Additionally, TNF alpha
levels were also measured in the plasma and other immune cell populations (CD4+ T
helper lymphocytes and CD8+ cytotoxic T lymphocytes). In all cases no differences in
TNF alpha levels were measured when comparing Cancer Pre, Control and Cancer Post
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groups. These data suggest that pro-inflammatory cytokine, TNF alpha is not altered
during periods of psychosocial distress.

IL-6 levels were also measured in ex vivo analysis of women with breast cancer.
Produced IL-6 was measured in both in the plasma and also by ex vivo stimulation of
peripheral PBMCs in the Cancer Pre and Control groups. No differences were measured
in the IL-6 levels in the plasma when comparing the Cancer Pre and Control groups. A
trend approaching significance of increased produced IL-6 levels was measured in the
Cancer Pre group when compared with the Control group (Supplemental Table 6). For
this assays total PBMCs were stimulated for 48 hours before supernatants were collected
and ELISA analysis determined produced IL-6 levels. Once trends in produced IL-6
were measured, intracellular flow cytometry was then used to determine which PBMC
sub population(s) was producing IL-6. Initial PBMC sub populations investigated were
NK cells, CD4+ T helper lymphocytes and CD8+ cytotoxic T lymphocytes, however
minimal intracellular IL-6 levels were detected in these PBMC sub populations. As a
result, intracellular IL-6 levels in CD14+ monocytes were also investigated. A
significant increase in the percentage of IL-6 producing CD14+ monocytes was measured
in the Cancer Pre group when compared to the Control group (Supplemental Table 6).
As intracellular IL-6 staining was not started until differences in produced levels were
observed, sample size limitations prevent comparison analysis with the Cancer Post
group. Analysis of intracellular IL-6 levels remains to be determined. It is also worth
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noting that although CD14+ monocyte cells produce IL-6, intracellular flow cytometric
analysis identified another population of PBMCs which also stained positively for
intracellular IL-6. This population has not been identified and remains a future direction;
however, NK cells, CD4+ T helper lymphocytes and CD8+ cytotoxic T lymphocytes
have been eliminated as possibilities. When the CD14+ monocytes were identified as an
IL-6 producing population of PBMCs, epigenetic analysis on this population also began.
Global H3-K9-Ac of CD14+ monocytes were measured by intracellular flow cytometry.
Global H3-K9-Ac patterns were investigated as relationships between H3 modifications
and IFN gamma were observed. No differences in global H3-K9-Ac levels in CD14+
monocytes were measured when comparing the Cancer Pre with the Control group.
Relationships were also investigated between percentage of IL-6 producing CD14+
monocytes and global H3-K9-Ac of CD14+ monocytes. Body mass index (BMI)
independently relates to IL-6 levels [206], therefore BMI was controlled for in correlation
analysis. Exploratory analysis between percentage of IL-6 producing CD14+ monocytes
and global H3-K9-Ac of CD14+ monocytes measured a positive relationship approaching
significance (Pearson r= 0.789, p=0.062, df=4) between these two variables. These data
suggests that global H3-K9-Ac patterns may relate to intracellular IL-6 levels in CD14+
monocytes. Additional analysis on CD14+ monocyte cells will confirm this result. The
data presented herein suggests that while H4-K8-Ac is associated with lytic activity,
modifications of H3 (H3-S10-p and H3-K9-Ac) may be associated with proinflammatory cytokines (IFN gamma and IL-6).
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Comparison of In Vitro and Ex Vivo Analysis:

In vitro analysis provided a screening tool for potential epigenetic modification
and chromatin remodeling proteins associated with altered GCs. As human samples were
limited, this served as a critical tool for determining which modifications and enzymes to
investigate as well as allowed for assay development. The chronic Dex treatment system
best reflected NK cell phenotypes observed in the Cancer Pre group and thus was most
utilized. Although the chronic Dex treatment system best represented the human cohorts,
it was not identical. For example, chronic Dex treatment reduced granzyme B levels in
NK92 cells, however no differences were measured in granzyme B levels in the NK cells
derived from the Cancer Pre group compared to the Control group. Additionally, NK92
cells produced IL-6, while NK cell derived from women with breast cancer produced
minimal IL-6.

The two in vitro systems allowed for the dose and time of GC exposure to NK
cells to be assessed, suggesting the NK cell lytic activity was impacted early in
treatments and is less dependent on GC levels. Both short-term, high dose and chronic
Dex treatment decreased NKCA of NK92 cells. Interestingly, the impact of GCs on proinflammatory cytokines was dose and time dependent, with short-term, high dose Dex
treatment decreasing IFN gamma levels and chronic Dex treatment increasing IFN
gamma levels. This differential effect would be more difficult to identify in the salivary
cortisol collections from the selected groups. Further analysis of the PBMCs derived
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from women with breast cancer did allow for assessment of multiple immune cell
populations, which was done in vitro. Finally comparison of the in vitro and ex vivo
systems highlights the importance of multiple systems to represent human data, but also
suggests that while model systems provide an important research tool they cannot
completely mimic systems in the human body.

CHAPTER 8
FUTURE DIRECTIONS
Identification of HDAC2 as a mediator of decreased global H4-K8-Ac and
decreased lytic activity in NK cells offers numerous therapeutic possibilities. Inhibition
of HDAC2 could be used in treatment of individual experiencing psychosocial distress,
exhibiting decreased NK cell function and/or women with breast cancer. The breast
cancer women enrolled in this study have early stage breast cancer, resulting in minimal
problems with tumor growth and progression. Therefore, a therapeutic inhibitor of
HDAC2 would most likely not be recommended for this population of women.
However, psychosocial distress and immune dysregulation measured in these women are
also measured in women with advanced metastatic breast cancer. It would be interesting
to investigate HDAC2 inhibitors as a means of increasing NK cell lytic activity to prevent
tumor cell growth and metastasis in women with advanced breast cancer. Interestingly, a
class of drugs termed HDAC inhibitors (HDACi) are already being investigated in a
number of different disease states, one of which is breast cancer [207, 208]. Nearly all
HDACis in clinical trials at this time interfere with activity of class I HDACs (HDAC1,
HDAC2, HDAC3 and HDAC8). Inhibition of HDACs in tumor cells has been associated
with decreased tumor cell proliferation and survival. Therefore, these HDACis offer
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therapeutic potential for women with metastatic breast cancer to decrease tumor cell
growth while simultaneously enhancing NK cell lytic activity.

Investigation into the upstream protein kinase(s) responsible for phosphorylation
of HDAC2 could also offer potential therapeutic opportunities. HDAC2 can be
phosphorylated at four different serine residues; 394, 411, 422 and 424 [209].
Phosphorylation of serines 394, 422 and 424 is associated with enzymatic activity, with
the link between phosphorylation of serine 394 (S394) being the strongest [176]. Casein
kinase 2 alpha 1 (CK2alpha1) has been identified as a protein kinase responsible for
phosphorylation of HDAC2 at S394 [176, 210]. Unlike other HDACs which can be
phosphorylated by a number of different kinases, CK2 is unique in its ability to
phosphorylate HDAC2. Investigation into CK2 activity could provide a novel pathway
to directly inhibit only HDAC2. The data present herein suggests that inhibiting CK2
and in turn HDAC2-p could also lead to increased NK cell lytic activity. Links between
NK cell and CK2 inhibitors are limited with one study measuring increased NK cell lytic
activity when target tumor cells were pre-treated with CK2 inhibitors [211].
Interestingly, this study measured increases in NK cell lytic activity to be associated with
death mediated ligands and not granule components. One potential future direction
could be to investigate if inhibition of CK2 impacts NK cell lytic activity, intracellular
perforin and global acetylation of H4-K8 in the presence of Dex. Additionally, CK2
activity has also been found to be elevated in cancer tissues [212]. Inhibition of CK2
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activity is associated with decreased tumor proliferation and envasion in both esophageal
and prostate cancer [213, 214]. CK2 promoted tumor cell growth by phosphorylation of
cellular proteins other than HDAC2. Relationships between CK2 and HDAC2-p in
tumor cell progression have not yet been identified. Although inhibition of CK2s in
breast cancer has not been investigated these results suggest that interfering with CK2
could also lead to decreased breast cancer cell growth. Together these data suggest that
CK2 inhibitors could also provide a novel cancer therapeutic by decreasing tumor cell
growth and increasing NK cell activity to individuals with cancer.

Relationships between PSS and GCs may not have been measured because GCs
may not have mediated the immunologic effects. Psychosocial distress upregulates other
neurotransmitters other than cortisol such as catecholamines. Stimulation of the
sympathetic nervous system results in the production of catecholamines such as
epinephrine and norepinepherine. Epinephrine and norepinepherine can impact immune
cells either through direct innervation of lymphoid organs or by secretion into the blood
stream [215]. Epinephrine and norepinepherine exert their effects through engagement
with beta-receptors [216]. There are five different beta-receptors that have been
indentified; beta 1, beta 2, beta 3, alpha 1 and alpha 2. These beta-receptors are G
coupled protein receptors that upon activation induce a signaling cascade leading to
increases in cAMP accumulation, activating protein kinase A within immune cells [217].
T lymphocytes, NK cells and B lymphocytes have all been shown to express beta 2

136

adrenergic receptor [218, 219]. The impact of these catecholamines on NK cells has not
been well investigated and results are varied. Some studies found catecholamines
decreased NK cell lytic function as measured by NKCA and mRNA levels of granzyme
B and perforin [217, 220]. Other studies found catecholamines increased NK cell activity
[221]. Analysis of epinephrine and norepinepherine on NK cell epigenetic modifications
remains to be investigated. As neurotransmitters, such as epinephrine and
norepinepherine, are upregulated during psychosocial distress understanding how
neurotransmitters impact NK cell function and epigenetic modifications, alone or in
combination with cortisol is a future direction for this laboratory.

CHAPTER 9
CONCLUSIONS
In sum, these results associate GC induced epigenetic histone modifications
with NK cell function. The acetylation status of H4-K8 was found to correlate with not
only NKCA but intracellular perforin levels in both ex vivo analysis of NK cells from
women with breast cancer and Dex treatment of NK92 cells. Increased nuclear HDAC2
was associated with decreased global H4-K8-Ac in NK cells, identifying HDAC2 as a
potential mediator of decreased global H4-K8-Ac. Additionally, a dichotomous
phenotype of decreased lytic activity and increased IFN gamma was also identified in NK
cells from women with breast cancer. This dichotomous phenotype correlated with
cortisol awaking rise, suggesting that activation of the HPA and cortisol production
mediates this effect. Exploratory analysis found that epigenetic modifications on H3 may
relate to increased IFN gamma. Identification of epigenetic modifications associated
with altered NK cell function highlights the importance of investigation into relationships
between the epigenome and psychosocial distress. Such analysis has not been previously
accomplished and this mechanistic insight will advance the science of
psychoneuroimmunology. In addition, the findings and technology generated from this
project can spur future translational studies that can develop epigenetic-based approaches
as potential indicators of immune cell function.

137

REFERENCES
1.

Chrousos, G.P., The stress response and immune function: clinical
implications. The 1999 Novera H. Spector Lecture. Ann N Y Acad Sci,
2000. 917: p. 38-67.

2.

Chrousos, G.P. and P.W. Gold, The concepts of stress and stress system
disorders. Overview of physical and behavioral homeostasis. Jama, 1992.
267(9): p. 1244-52.

3.

Schoneveld, O. and J.A. Cidlowski, Glucocorticoids and immunity:
mechanisms of regulation, in Psychoneuroimmunology, R. Ader, Editor.
2007, Elsevier Academic Press: Burlington, MA. p. 45-61.

4.

Holbrook, N.J., W.I. Cox, and H.C. Horner, Direct suppression of natural
killer activity in human peripheral blood leukocyte cultures by
glucocorticoids and its modulation by interferon. Cancer Res, 1983. 43(9):
p. 4019-25.

5.

Mathews, H.L. and L.W. Janusek, Epigenetics and
psychoneuroimmunology: mechanisms and models. Brain Behav Immun,
2011. 25(1): p. 25-39.

6.

Krukowski, K., et al., Glucocorticoid Dysregulates Natural Killer Cell
Function through Epigenetic Modification. Brain Behavior and Immunity,
2011. 25(2): p. 239-249.

7.

Snyers, L., L. De Wit, and J. Content, Glucocorticoid up-regulation of
high-affinity interleukin 6 receptors on human epithelial cells. Proc Natl
Acad Sci U S A, 1990. 87(7): p. 2838-42.

8.

Strickland, R.W., L.M. Wahl, and D.S. Finbloom, Corticosteroids
enhance the binding of recombinant interferon-gamma to cultured human
monocytes. Journal of Immunology, 1986. 137(5): p. 1577-80.
138

139

9.

Yeager, M.P., et al., In vivo exposure to high or low cortisol has biphasic
effects on inflammatory response pathways of human monocytes. Anesth
Analg, 2008. 107(5): p. 1726-34.

10.

Arima, M., et al., Expression of interleukin-16 by human epithelial cells.
Inhibition by dexamethasone. Am J Respir Cell Mol Biol, 1999. 21(6): p.
684-92.

11.

Elenkov, I.J., et al., Modulatory effects of glucocorticoids and
catecholamines on human interleukin-12 and interleukin-10 production:
clinical implications. Proc Assoc Am Physicians, 1996. 108(5): p. 374-81.

12.

Haynesworth, S.E., M.A. Baber, and A.I. Caplan, Cytokine expression by
human marrow-derived mesenchymal progenitor cells in vitro: effects of
dexamethasone and IL-1 alpha. J Cell Physiol, 1996. 166(3): p. 585-92.

13.

Bower, J.E., Behavioral symptoms in patients with breast cancer and
survivors. J Clin Oncol, 2008. 26(5): p. 768-77.

14.

Witek-Janusek, L., et al., Effect of mindfulness based stress reduction on
immune function, quality of life and coping in women newly diagnosed
with early stage breast cancer. Brain Behav Immun, 2008. 22(6): p. 96981.

15.

Witek-Janusek, L., S. Gabram, and H.L. Mathews, Psychologic stress,
reduced NK cell activity, and cytokine dysregulation in women
experiencing diagnostic breast biopsy. Psychoneuroendocrinology, 2007.
32(1): p. 22-35.

16.

Shapiro, S.L., et al., Quality of life and breast cancer: relationship to
psychosocial variables. J Clin Psychol, 2001. 57(4): p. 501-19.

17.

Ancoli-Israel, S., et al., Fatigue, sleep, and circadian rhythms prior to
chemotherapy for breast cancer. Support Care Cancer, 2006. 14(3): p.
201-9.

140

18.

Gerber, B., M. Freund, and T. Reimer, Recurrent breast cancer: treatment
strategies for maintaining and prolonging good quality of life. Dtsch
Arztebl Int, 2010. 107(6): p. 85-91.

19.

Barnes, P.J., Anti-inflammatory actions of glucocorticoids: molecular
mechanisms. Clin Sci (Lond), 1998. 94(6): p. 557-72.

20.

Society, A.C. 2011; Available from:
http://www.cancer.org/Research/CancerFactsFigures/index.

21.

Parkin, D.M., et al., Global cancer statistics, 2002. CA Cancer J Clin,
2005. 55(2): p. 74-108.

22.

Luecken, L.J. and B.E. Compas, Stress, coping, and immune function in
breast cancer. Ann Behav Med, 2002. 24(4): p. 336-44.

23.

Stark, D.P. and A. House, Anxiety in cancer patients. Br J Cancer, 2000.
83(10): p. 1261-7.

24.

Northouse, L.L., Psychological impact of the diagnosis of breast cancer
on the patient and her family. J Am Med Womens Assoc, 1992. 47(5): p.
161-4.

25.

Pettingale, K.W., C. Burgess, and S. Greer, Psychological response to
cancer diagnosis--I. Correlations with prognostic variables. J Psychosom
Res, 1988. 32(3): p. 255-61.

26.

Beatty, L., et al., The psychosocial concerns and needs of women recently
diagnosed with breast cancer: a qualitative study of patient, nurse and
volunteer perspectives. Health Expect, 2008. 11(4): p. 331-42.

27.

Rakovitch, E., et al., A comparison of risk perception and psychological
morbidity in women with ductal carcinoma in situ and early invasive
breast cancer. Breast Cancer Res Treat, 2003. 77(3): p. 285-93.

141

28.

Becker JB, B.S., Crews D, ed. Neuroendocrinology of the stress-response.
Behavioural endocrinology. 1992, MIT Press. 287-324.

29.

Mason, J.W., A review of psychoendocrine research on the pituitaryadrenal cortical system. Psychosomatic Medicine, 1968. 30(5): p.
Suppl:576-607.

30.

Segerstrom, S.C. and G.E. Miller, Psychological stress and the human
immune system: a meta-analytic study of 30 years of inquiry. Psychol
Bull, 2004. 130(4): p. 601-30.

31.

Dhabhar, F.S., Stress, leukocyte trafficking, and the augmentation of skin
immune function. Ann N Y Acad Sci, 2003. 992: p. 205-17.

32.

Dopp, J.M., et al., Increased natural killer-cell mobilization and
cytotoxicity during marital conflict. Brain Behav Immun, 2000. 14(1): p.
10-26.

33.

Webster, J.I., L. Tonelli, and E.M. Sternberg, Neuroendocrine regulation
of immunity. Annu Rev Immunol, 2002. 20: p. 125-63.

34.

Bailey, et al., The hypothalamic-pituitary-adrenal axis and viral infection.
Viral Immunol., 2003. 16: p. 141-157.

35.

Ader, R., Psychoneuroimmunology. 4th ed. 2007, San Diego: Academic
Press.

36.

Glaser, R. and J.K. Kiecolt-Glaser, Stress-induced immune dysfunction:
implications for health. Nat Rev Immunol, 2005. 5(3): p. 243-51.

37.

Dhabhar, F.S. and B.S. McEwen, Bi-directional effects of stress on
immune fuction: Possible explanations for salubrious as well as harmful
effects., in Psychoneuroimmunology, R. Ader, Editor. 2007, Elsevier
Academic Press: Burlington, MA. p. 723-760.

142

38.

Dhabhar, F.S., Enhancing versus Suppressive Effects of Stress on Immune
Function: Implications for Immunoprotection versus Immunopathology.
Allergy Asthma Clin Immunol, 2008. 4(1): p. 2-11.

39.

Henselmans, I., et al., Identification and prediction of distress trajectories
in the first year after a breast cancer diagnosis. Health Psychology, 2010.
29(2): p. 160-8.

40.

Karatsoreos, I.N. and B.S. McEwen, Psychobiological allostasis:
resistance, resilience and vulnerability. Trends Cogn Sci, 2011. 15(12): p.
576-84.

41.

Omne-Ponten, M., L. Holmberg, and P.O. Sjoden, Psychosocial
adjustment among women with breast cancer stages I and II: six-year
follow-up of consecutive patients. J Clin Oncol, 1994. 12(9): p. 1778-82.

42.

Parente, V., L. Hale, and T. Palermo, Association between breast cancer
and allostatic load by race: National Health and Nutrition Examination
Survey 1999-2008. Psycho-Oncology, 2012.

43.

Bower, J.E., et al., Fatigue in breast cancer survivors: occurrence,
correlates, and impact on quality of life. J Clin Oncol, 2000. 18(4): p. 74353.

44.

Ganz, P.A., et al., Impact of different adjuvant therapy strategies on
quality of life in breast cancer survivors. Recent Results Cancer Res,
1998. 152: p. 396-411.

45.

Miller, G.E., et al., A Functional Genomic Fingerprint of Chronic Stress
in Humans: Blunted Glucocorticoid and Increased NF-kappaB Signaling.
Biol Psychiatry, 2008. 64: p. 266-272.

46.

McEwen, B.S., et al., The role of adrenocorticoids as modulators of
immune function in health and disease: neural, endocrine and immune
interactions. Brain Res Brain Res Rev, 1997. 23(1-2): p. 79-133.

143

47.

Freedman, N.D. and K.R. Yamamoto, Importin 7 and importin
alpha/importin beta are nuclear import receptors for the glucocorticoid
receptor. Molecular Biology of the Cell, 2004. 15(5): p. 2276-86.

48.

Ito, K., P.J. Barnes, and I.M. Adcock, Glucocorticoid receptor recruitment
of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4
acetylation on lysines 8 and 12. Mol Cell Biol, 2000. 20(18): p. 6891-903.

49.

Bush, K.A., Krukowski, K., Eddy, J.L., Witek Janusek, L., Mathews, H.L.,
Glucocorticoid receptor mediated suppression of natural killer cell
activity: Identification of associated deacetylase and corepressor
molecules. Cellular Immunology, 2012(Under Review).

50.

Longworth, M.S. and L.A. Laimins, Histone deacetylase 3 localizes to the
plasma membrane and is a substrate of Src. Oncogene, 2006. 25(32): p.
4495-500.

51.

Islam, K.N. and C.R. Mendelson, Glucocorticoid/glucocorticoid receptor
inhibition of surfactant protein-A (SP-A) gene expression in lung type II
cells is mediated by repressive changes in histone modification at the SPA promoter. Molecular Endocrinology, 2008. 22(3): p. 585-96.

52.

Sephton, S.E., et al., Diurnal cortisol rhythm as a predictor of breast
cancer survival. J Natl Cancer Inst, 2000. 92(12): p. 994-1000.

53.

Bower, J.E., et al., Diurnal cortisol rhythm and fatigue in breast cancer
survivors. Psychoneuroendocrinology, 2005. 30(1): p. 92-100.

54.

Clow, A., F. Hucklebridge, and L. Thorn, The cortisol awakening
response in context. International Review of Neurobiology, 2010. 93: p.
153-75.

55.

Pruessner, J.C., et al., Free cortisol levels after awakening: a reliable
biological marker for the assessment of adrenocortical activity. Life
Sciences, 1997. 61(26): p. 2539-49.

144

56.

Spijker, A.T. and E.F. van Rossum, Glucocorticoid sensitivity in mood
disorders. Neuroendocrinology, 2012. 95(3): p. 179-86.

57.

Chida, Y. and A. Steptoe, Cortisol awakening response and psychosocial
factors: a systematic review and meta-analysis. Biological Psychology,
2009. 80(3): p. 265-78.

58.

Hsiao, F.H., et al., A longitudinal study of cortisol responses, sleep
problems, and psychological well-being as the predictors of changes in
depressive symptoms among breast cancer survivors.
Psychoneuroendocrinology, 2012.

59.

Miller, G.E., E. Chen, and E.S. Zhou, If it goes up, must it come down?
Chronic stress and the hypothalamic-pituitary-adrenocortical axis in
humans. Psychol Bull, 2007. 133(1): p. 25-45.

60.

Abercrombie, H.C., et al., Flattened cortisol rhythms in metastatic breast
cancer patients. Psychoneuroendocrinology, 2004. 29(8): p. 1082-92.

61.

Dedert, E., et al., Stress, coping, and circadian disruption among women
awaiting breast cancer surgery. Annals of Behavioral Medicine, 2012.
44(1): p. 10-20.

62.

Saban, K.L., et al., Depressive Symptoms and Diurnal Salivary Cortisol
Patterns Among Female Caregivers of Stroke Survivors. Biol Res Nurs,
2012.

63.

Biondi, M., Effects of stress on immune functions: An overview, in
Psychoneuroimmunology, R. Ader and N. Cohen, Editors. 2001,
Academic Press: New York. p. 189-226.

64.

Esterling, B.A., et al., Chronic stress, social support, and persistent
alterations in the natural killer cell response to cytokines in older adults.
Health Psychol., 1994. 13(4): p. 291-8.

145

65.

Esterling, B.A., J.K. Kiecolt-Glaser, and R. Glaser, Psychosocial
modulation of cytokine-induced natural killer cell activity in older adults.
Psychosom. Med., 1996. 58(3): p. 264-72.

66.

Herbert, T.B. and S. Cohen, Depression and immunity: a meta-analytic
review. Psychol Bull, 1993. 113(3): p. 472-86.

67.

Witek-Janusek, L. and H.L. Mathews, Stress, Immunity, and Health
Outcomes, in Handbook of Stress, Coping, and Health: Implications for
Nursing Research, Theory, and Practice, V. Rice, Editor. 2000, Sage
Publications: Thousand Oaks. p. 47-67.

68.

Maes, M., et al., Elevated serum interleukin-6 (IL-6) and IL-6 receptor
concentrations in posttraumatic stress disorder following accidental manmade traumatic events. Biol Psychiatry, 1999. 45(7): p. 833-9.

69.

Marshall, G.D., Jr., et al., Cytokine dysregulation associated with exam
stress in healthy medical students. Brain Behav. Immun., 1998. 12(4): p.
297-307.

70.

Kiecolt-Glaser, J.K., et al., Spousal caregivers of dementia victims:
longitudinal changes in immunity and health. Psychosom Med, 1991.
53(4): p. 345-62.

71.

Andersen, B.L., et al., Stress and immune responses after surgical
treatment for regional breast cancer. J. Natl. Cancer Inst., 1998. 90(1): p.
30-6.

72.

Andersen, B.L., et al., Psychological, behavioral, and immune changes
after a psychological intervention: a clinical trial. J Clin Oncol, 2004.
22(17): p. 3570-80.

73.

Kiecolt-Glaser, J.K., et al., Chronic stress alters the immune response to
influenza virus vaccine in older adults. Proc Natl Acad Sci U S A, 1996.
93(7): p. 3043-7.

146

74.

Glaser, R., et al., Stress depresses interferon production by leukocytes
concomitant with a decrease in natural killer cell activity. Behav.
Neurosci., 1986. 100(5): p. 675-8.

75.

Larson, M.R., et al., A presurgical psychosocial intervention for breast
cancer patients. psychological distress and the immune response. J
Psychosom Res, 2000. 48(2): p. 187-94.

76.

Boumpas, D.T., et al., Glucocorticoid therapy for immune-mediated
diseases: basic and clinical correlates. Ann Intern Med, 1993. 119(12): p.
1198-208.

77.

Sorrells, S.F. and R.M. Sapolsky, An inflammatory review of
glucocorticoid actions in the CNS. Brain Behav Immun, 2007. 21(3): p.
259-72.

78.

Sapolsky, R.M., Glucocorticoids, stress, and their adverse neurological
effects: relevance to aging. Exp Gerontol, 1999. 34(6): p. 721-32.

79.

Loram, L.C., et al., Prior exposure to glucocorticoids potentiates
lipopolysaccharide induced mechanical allodynia and spinal
neuroinflammation. Brain Behav Immun, 2011.

80.

Frank, M.G., L.R. Watkins, and S.F. Maier, Stress- and glucocorticoidinduced priming of neuroinflammatory responses: potential mechanisms
of stress-induced vulnerability to drugs of abuse. Brain Behav Immun,
2011. 25 Suppl 1: p. S21-8.

81.

Frank, M.G., et al., Prior exposure to glucocorticoids sensitizes the
neuroinflammatory and peripheral inflammatory responses to E. coli
lipopolysaccharide. Brain Behav Immun, 2010. 24(1): p. 19-30.

82.

Altemus, M., et al., Stress-induced changes in skin barrier function in
healthy women. J Invest Dermatol, 2001. 117(2): p. 309-17.

147

83.

Mekaouche, M., et al., Chronic restraint enhances interleukin-1-beta
release in the basal state and after an endotoxin challenge, independently
of adrenocorticotropin and corticosterone release.
Neuroimmunomodulation, 1994. 1(5): p. 292-9.

84.

Takaki, A., et al., Immobilization stress may increase plasma interleukin-6
via central and peripheral catecholamines. Neuroimmunomodulation,
1994. 1(6): p. 335-42.

85.

Baumann, H. and J. Gauldie, The acute phase response. Immunol Today,
1994. 15(2): p. 74-80.

86.

Wiegers, G.J. and J.M. Reul, Induction of cytokine receptors by
glucocorticoids: functional and pathological significance. Trends
Pharmacol Sci, 1998. 19(8): p. 317-21.

87.

Sapolsky, R.M., L.M. Romero, and A.U. Munck, How do glucocorticoids
influence stress responses? Integrating permissive, suppressive,
stimulatory, and preparative actions. Endocr Rev, 2000. 21(1): p. 55-89.

88.

Guyre, P., M. Yeager, and A. Munck, Glucocorticoid effects on immune
responses. Neuroimmune Biology, 2008(7): p. 147-168.

89.

Yeager, M.P., P.M. Guyre, and A.U. Munck, Glucocorticoid regulation of
the inflammatory response to injury. Acta Anaesthesiologica
Scandinavica, 2004. 48(7): p. 799-813.

90.

Sorrells, S.F. and R.M. Sapolsky, Glucocorticoids can arm macrophages
for innate immune battle. Brain, Behavior, and Immunity, 2010. 24(1): p.
17-8.

91.

Cooper, M.A., T.A. Fehniger, and M.A. Caligiuri, The biology of human
natural killer-cell subsets. Trends Immunol, 2001. 22(11): p. 633-40.

148

92.

Konjevic, G., et al., Analysis of perforin expression in human peripheral
blood lymphocytes, CD56+ natural killer cell subsets and its induction by
interleukin-2. Immunol Invest, 1995. 24(3): p. 499-507.

93.

Biron, C.A., Initial and innate responses to viral infections--pattern
setting in immunity or disease. Curr Opin Microbiol, 1999. 2(4): p. 37481.

94.

Gumperz, J.E. and P. Parham, The enigma of the natural killer cell.
Nature, 1995. 378(6554): p. 245-8.

95.

Trinchieri, G., Biology of natural killer cells. Adv Immunol, 1989. 47: p.
187-376.

96.

Alexandroff, A.B., et al., Tumour immunology: false hopes--new
horizons? Immunol Today, 1998. 19(6): p. 247-50.

97.

Dighe, A.S., et al., Enhanced in vivo growth and resistance to rejection of
tumor cells expressing dominant negative IFN gamma receptors.
Immunity, 1994. 1(6): p. 447-56.

98.

Kagi, D., et al., Cytotoxicity mediated by T cells and natural killer cells is
greatly impaired in perforin-deficient mice. Nature, 1994. 369(6475): p.
31-7.

99.

Kaplan, D.H., et al., Demonstration of an interferon gamma-dependent
tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci
U S A, 1998. 95(13): p. 7556-61.

100.

Smyth, M.J., et al., An essential role for tumor necrosis factor in natural
killer cell-mediated tumor rejection in the peritoneum. J Exp Med, 1998.
188(9): p. 1611-9.

101.

Smyth, M.J., et al., Perforin is a major contributor to NK cell control of
tumor metastasis. J. Immunol., 1999. 162(11): p. 6658-62.

149

102.

Street, S.E., E. Cretney, and M.J. Smyth, Perforin and interferon-gamma
activities independently control tumor initiation, growth, and metastasis.
Blood, 2001. 97(1): p. 192-7.

103.

van den Broek, M.E., et al., Decreased tumor surveillance in perforindeficient mice. J. Exp. Med., 1996. 184(5): p. 1781-90.

104.

Seki, N., et al., Tumor necrosis factor-related apoptosis-inducing ligandmediated apoptosis is an important endogenous mechanism for resistance
to liver metastases in murine renal cancer. Cancer Res, 2003. 63(1): p.
207-13.

105.

Kiecolt-Glaser, J.K., et al., Chronic stress and immunity in family
caregivers of Alzheimer's disease victims. Psychosom Med, 1987. 49(5):
p. 523-35.

106.

Fawzy, F.I., et al., A structured psychiatric intervention for cancer
patients. II. Changes over time in immunological measures. Arch Gen
Psychiatry, 1990. 47(8): p. 729-35.

107.

Thornton, L.M., et al., Individual trajectories in stress covary with
immunity during recovery from cancer diagnosis and treatments. Brain
Behav Immun, 2007. 21(2): p. 185-94.

108.

Varker, K.A., et al., Impaired natural killer cell lysis in breast cancer
patients with high levels of psychological stress is associated with altered
expression of killer immunoglobin-like receptors. J Surg Res, 2007.
139(1): p. 36-44.

109.

Gonzales, F.M., et al., Prognostic significance of natural killer cell
activity in patients with laryngeal carcinoma. Arch Otolaryngol Head
Neck Surg, 1998. 124: p. 852-856.

110.

Koda, K., et al., Preoperative natural killer cell activity: correlation with
distant metastases in curatively research colorectal carcinomas. Int Surg,
1997. 82(2): p. 190-3.

150

111.

Liljefors, M., et al., Natural killer (NK) cell function is a strong prognostic
factor in colorectal carcinoma patients treated with the monoclonal
antibody 17-1A. Int J Cancer, 2003. 105(5): p. 717-23.

112.

Nakamura, H., et al., Cellular immunologic parameters related to age,
gender, and stage in lung cancer patients. Lung Cancer, 2000. 28(2): p.
139-45.

113.

Seo, N. and Y. Tokura, Downregulation of innate and acquired antitumor
immunity by bystander gammadelta and alphabeta T lymphocytes with
Th2 or Tr1 cytokine profiles. J Interferon Cytokine Res, 1999. 19(6): p.
555-61.

114.

Taketomi, A., et al., Natural killer cell activity in patients with
hepatocellular carcinoma: a new prognostic indicator after hepatectomy.
Cancer, 1998. 83(1): p. 58-63.

115.

Vivier, E., et al., Innate or adaptive immunity? The example of natural
killer cells. Science, 2011. 331(6013): p. 44-9.

116.

Waddington, C., Endeavour 1. The Epigenotype. 1942. 18-20.

117.

Hunter, R.G., Epigenetic effects of stress and corticosteroids in the brain.
Front Cell Neurosci, 2012. 6: p. 18.

118.

Luger, K., et al., Crystal structure of the nucleosome core particle at 2.8 A
resolution. Nature, 1997. 389(6648): p. 251-60.

119.

Spencer, V.A. and J.R. Davie, Role of covalent modifications of histones
in regulating gene expression. Gene, 1999. 240(1): p. 1-12.

120.

Strahl, B.D. and C.D. Allis, The language of covalent histone
modifications. Nature, 2000. 403(6765): p. 41-5.

151

121.

Alfrey, C.P., Jr., et al., Erythrokinetic Abnormalities with Administration
of Hydroxyurea (Nsc-32065). Cancer Chemother Rep, 1964. 40: p. 27-30.

122.

Berger, S.L., The complex language of chromatin regulation during
transcription. Nature, 2007. 447(7143): p. 407-12.

123.

Kornberg, R.D. and Y. Lorch, Chromatin-modifying and -remodeling
complexes. Curr Opin Genet Dev, 1999. 9(2): p. 148-51.

124.

Ura, K., et al., Histone acetylation: influence on transcription, nucleosome
mobility and positioning, and linker histone-dependent transcriptional
repression. Embo J, 1997. 16(8): p. 2096-107.

125.

Avni, O., et al., T(H) cell differentiation is accompanied by dynamic
changes in histone acetylation of cytokine genes. Nat Immunol, 2002.
3(7): p. 643-51.

126.

Araki, Y., et al., Histone acetylation facilitates rapid and robust memory
CD8 T cell response through differential expression of effector molecules
(eomesodermin and its targets: perforin and granzyme B). Journal of
Immunology, 2008. 180(12): p. 8102-8.

127.

Santourlidis, S., et al., Lineage-specific transition of histone signatures in
the killer cell Ig-like receptor locus from hematopoietic progenitor to NK
cells. J Immunol, 2008. 180(1): p. 418-25.

128.

Matthews, J.G., et al., Defective glucocorticoid receptor nuclear
translocation and altered histone acetylation patterns in glucocorticoidresistant patients. J Allergy Clin Immunol, 2004. 113(6): p. 1100-8.

129.

Tsaprouni, L.G., et al., Triamcinolone acetonide and dexamethasome
suppress TNF-alpha-induced histone H4 acetylation on lysine residues 8
and 12 in mononuclear cells. Ann N Y Acad Sci, 2002. 973: p. 481-3.

152

130.

Soliman, M.L., et al., Acetate supplementation modulates brain histone
acetylation and decreases interleukin-1beta expression in a rat model of
neuroinflammation. J Neuroinflammation, 2012. 9: p. 51.

131.

Kagoshima, M., et al., Glucocorticoid-mediated transrepression is
regulated by histone acetylation and DNA methylation. Eur J Pharmacol,
2001. 429(1-3): p. 327-34.

132.

Mishra, N., et al., Trichostatin A reverses skewed expression of CD154,
interleukin-10, and interferon-gamma gene and protein expression in
lupus T cells. Proc Natl Acad Sci U S A, 2001. 98(5): p. 2628-33.

133.

Plesko, M.M., et al., Inhibition by sodium butyrate of enzyme induction by
glucocorticoids and dibutyryl cyclic AMP. A role for the rapid form of
histone acetylation. J Biol Chem, 1983. 258(22): p. 13738-44.

134.

Brogdon, J.L., et al., Histone deacetylase activities are required for innate
immune cell control of Th1 but not Th2 effector cell function. Blood, 2007.
109(3): p. 1123-30.

135.

Gregoretti, I.V., Y.M. Lee, and H.V. Goodson, Molecular evolution of the
histone deacetylase family: functional implications of phylogenetic
analysis. Journal of Molecular Biology, 2004. 338(1): p. 17-31.

136.

Allis, C.D., et al., New nomenclature for chromatin-modifying enzymes.
Cell, 2007. 131(4): p. 633-6.

137.

Kouzarides, T., Chromatin modifications and their function. Cell, 2007.
128(4): p. 693-705.

138.

Jones, P.L., et al., Multiple N-CoR complexes contain distinct histone
deacetylases. Journal of Biological Chemistry, 2001. 276(12): p. 8807-11.

139.

Yang, W.M., et al., Functional domains of histone deacetylase-3. Journal
of Biological Chemistry, 2002. 277(11): p. 9447-54.

153

140.

Hong, W., et al., Bag-1M inhibits the transactivation of the glucocorticoid
receptor via recruitment of corepressors. FEBS Lett, 2009. 583(15): p.
2451-6.

141.

Ning, Z.Q., et al., Chidamide (CS055/HBI-8000): a new histone
deacetylase inhibitor of the benzamide class with antitumor activity and
the ability to enhance immune cell-mediated tumor cell cytotoxicity.
Cancer Chemotherapy and Pharmacology, 2012. 69(4): p. 901-9.

142.

Levine, A., et al., Early life stress triggers sustained changes in histone
deacetylase expression and histone H4 modifications that alter
responsiveness to adolescent antidepressant treatment. Neurobiol Dis,
2012. 45(1): p. 488-98.

143.

Yang, H., et al., Dexamethasone-induced protein degradation in cultured
myotubes is p300/HAT dependent. Am J Physiol Regul Integr Comp
Physiol, 2007. 292(1): p. R337-4.

144.

Bannister, A.J. and T. Kouzarides, The CBP co-activator is a histone
acetyltransferase. Nature, 1996. 384(6610): p. 641-3.

145.

Chen, H., et al., Nuclear receptor coactivator ACTR is a novel histone
acetyltransferase and forms a multimeric activation complex with P/CAF
and CBP/p300. Cell, 1997. 90(3): p. 569-80.

146.

Ogryzko, V.V., et al., The transcriptional coactivators p300 and CBP are
histone acetyltransferases. Cell, 1996. 87(5): p. 953-9.

147.

Selvi, R.B. and T.K. Kundu, Reversible acetylation of chromatin:
implication in regulation of gene expression, disease and therapeutics.
Biotechnol J, 2009. 4(3): p. 375-90.

148.

Roth, S.Y., J.M. Denu, and C.D. Allis, Histone acetyltransferases. Annu
Rev Biochem, 2001. 70: p. 81-120.

154

149.

Beno, D.W., A.G. Stover, and H.L. Mathews, Growth inhibition of
Candida albicans hyphae by CD8+ lymphocytes. J. Immunol., 1995.
154(10): p. 5273-81.

150.

Yamamura, Y., et al., A new flow cytometric method for quantitative
assessment of lymphocyte mitogenic potentials. Cell Mol Biol, 1995.
41(Suppl 1): p. S121-32.

151.

Nagabhushan, M., H.L. Mathews, and L. Witek-Janusek, Aberrant nuclear
expression of ap-1 and nfkb in lymphocytes of women stressed by the
experience of breast biopsy. Brain Behav. Immun., 2001. 15(1): p. 78-84.

152.

Cavarec, L., et al., An improved double fluorescence flow cytometry
method for the quantification of killer cell/target cell conjugate formation.
J Immunol Methods, 1990. 130(2): p. 251-61.

153.

Whelan, R.L., et al., Postoperative cell mediated immune response is
better preserved after laparoscopic vs open colorectal resection in
humans. Surg Endosc, 2003. 17(6): p. 972-8.

154.

Wichmann, M.W., et al., Detrimental immunologic effects of preoperative
chemoradiotherapy in advanced rectal cancer. Dis Colon Rectum, 2003.
46(7): p. 875-87.

155.

Mokart, D., et al., Early postoperative compensatory anti-inflammatory
response syndrome is associated with septic complications after major
surgical trauma in patients with cancer. Br J Surg, 2002. 89(11): p. 14506.

156.

Decker, D., et al., Surgical stress induces a shift in the type-1/type-2 Thelper cell balance, suggesting down-regulation of cell-mediated and upregulation of antibody-mediated immunity commensurate to the trauma.
Surgery, 1996. 119(3): p. 316-25.

155

157.

Kutza, J., et al., The effects of general anesthesia and surgery on basal
and interferon stimulated natural killer cell activity of humans. Anesth
Analg, 1997. 85(4): p. 918-23.

158.

Pollock, R.E., E. Lotzova, and S.D. Stanford, Mechanism of surgical
stress impairment of human perioperative natural killer cell cytotoxicity.
Arch Surg, 1991. 126(3): p. 338-42.

159.

Koltun, W.A., et al., Awake epidural anesthesia is associated with
improved natural killer cell cytotoxicity and a reduced stress response.
Am J Surg, 1996. 171(1): p. 68-72; discussion 72-3.

160.

Shakhar, G. and S. Ben-Eliyahu, Potential prophylactic measures against
postoperative immunosuppression: could they reduce recurrence rates in
oncological patients? Ann Surg Oncol, 2003. 10(8): p. 972-92.

161.

Spies, C.D., et al., Altered cell-mediated immunity and increased
postoperative infection rate in long-term alcoholic patients.
Anesthesiology, 2004. 100(5): p. 1088-100.

162.

Homburger, J.A. and S.E. Meiler, Anesthesia drugs, immunity, and longterm outcome. Curr Opin Anaesthesiol, 2006. 19(4): p. 423-8.

163.

Cohen, S., T. Kamarck, and R. Mermelstein, A global measure of
perceived stress. J Health Soc Behav, 1983. 24(4): p. 385-96.

164.

Cohen, S. and G.M. Williamson, Perceived stress in a probability sample
of the United States. The Social Psychology of Health, 1988: p. 31-67.

165.

Radloff, L.S., The CES-D Scale: A self-report depression scale for
research in the general population. Applied Psychological Measurement,
1977. 1: p. 385-401.

166.

Fann, J.R., et al., Major depression after breast cancer: a review of
epidemiology and treatment. Gen Hosp Psychiatry, 2008. 30(2): p. 112-26.

156

167.

Costanzo, E.S., et al., Adjusting to life after treatment: distress and quality
of life following treatment for breast cancer. Br J Cancer, 2007. 97(12): p.
1625-31.

168.

Hann, D., K. Winter, and P. Jacobsen, Measurement of depressive
symptoms in cancer patients: evaluation of the Center for Epidemiological
Studies Depression Scale (CES-D). J Psychosom Res, 1999. 46(5): p. 43743.

169.

Mundy-Bosse, B.L., et al., Psychological stress is associated with altered
levels of myeloid-derived suppressor cells in breast cancer patients.
Cellular Immunology, 2011. 270(1): p. 80-7.

170.

Kraemer, H.C., et al., Design decisions to optimize reliability of daytime
cortisol slopes in an older population. Am J Geriatr Psychiatry, 2006.
14(4): p. 325-33.

171.

Kudielka, B.M. and C. Kirschbaum, Awakening cortisol responses are
influenced by health status and awakening time but not by menstrual cycle
phase. Psychoneuroendocrinology, 2003. 28(1): p. 35-47.

172.

Cohen, S., et al., Socioeconomic status, race, and diurnal cortisol decline
in the Coronary Artery Risk Development in Young Adults (CARDIA)
Study. Psychosom Med, 2006. 68(1): p. 41-50.

173.

Kiecolt-Glaser, J.K., et al., Emotions, morbidity, and mortality: new
perspectives from psychoneuroimmunology. Annu Rev Psychol, 2002. 53:
p. 83-107.

174.

Zheng, X., et al., LFA-1 and CD2 synergize for the Erk1/2 activation in
the Natural Killer (NK) cell immunological synapse. J Biol Chem, 2009.
284(32): p. 21280-7.

175.

Orange, J.S. and Z.K. Ballas, Natural killer cells in human health and
disease. Clin Immunol, 2006. 118(1): p. 1-10.

157

176.

Eom, G.H., et al., Casein kinase-2alpha1 induces hypertrophic response
by phosphorylation of histone deacetylase 2 S394 and its activation in the
heart. Circulation, 2011. 123(21): p. 2392-403.

177.

van der Pompe, G., et al., Effectiveness of a short-term group
psychotherapy program on endocrine and immune function in breast
cancer patients: an exploratory study. Journal of Psychosomatic Research,
1997. 42(5): p. 453-66.

178.

Onsrud, M. and E. Thorsby, Influence of in vivo hydrocortisone on some
human blood lymphocyte subpopulations. I. Effect on natural killer cell
activity. Scand J Immunol, 1981. 13(6): p. 573-9.

179.

Ben-Eliyahu, S., et al., Evidence that stress and surgical interventions
promote tumor development by suppressing natural killer cell activity. Int
J Cancer, 1999. 80(6): p. 880-8.

180.

De Gucht, V., B. Fischler, and C. Demanet, Immune dysfunction
associated with chronic professional stress in nurses. Psychiatry Res,
1999. 85(1): p. 105-11.

181.

Gan, X., et al., Mechanism of norepinephrine-mediated inhibition of
human NK cytotoxic functions: inhibition of cytokine secretion, target
binding, and programming for cytotoxicity. Brain Behav Immun, 2002.
16(3): p. 227-46.

182.

Gatti, G., et al., Inhibition by cortisol of human natural killer (NK) cell
activity. J Steroid Biochem, 1987. 26(1): p. 49-58.

183.

Adcock, I.M., Glucocorticoid-regulated transcription factors. Pulm
Pharmacol Ther, 2001. 14(3): p. 211-9.

184.

Almawi, W.Y. and O.K. Melemedjian, Molecular mechanisms of
glucocorticoid antiproliferative effects: antagonism of transcription factor
activity by glucocorticoid receptor. J Leukoc Biol, 2002. 71(1): p. 9-15.

158

185.

Wang, J.C., et al., Chromatin immunoprecipitation (ChIP) scanning
identifies primary glucocorticoid receptor target genes. Proc Natl Acad
Sci U S A, 2004. 101(44): p. 15603-8.

186.

Franchimont, D., Overview of the actions of glucocorticoids on the
immune response: a good model to characterize new pathways of
immunosuppression for new treatment strategies. Ann N Y Acad Sci,
2004. 1024: p. 124-37.

187.

Barnes, P.J. and I.M. Adcock, Transcription factors and asthma. Eur
Respir J, 1998. 12(1): p. 221-34.

188.

Ray, A. and K.E. Prefontaine, Physical association and functional
antagonism between the p65 subunit of transcription factor NF-kappa B
and the glucocorticoid receptor. Proc Natl Acad Sci U S A, 1994. 91(2):
p. 752-6.

189.

Truss, M. and M. Beato, Steroid hormone receptors: interaction with
deoxyribonucleic acid and transcription factors. Endocr Rev, 1993. 14(4):
p. 459-79.

190.

Ito, K., et al., p65-activated histone acetyltransferase activity is repressed
by glucocorticoids: mifepristone fails to recruit HDAC2 to the p65-HAT
complex. J Biol Chem, 2001. 276(32): p. 30208-15.

191.

Cippitelli, M., et al., Negative transcriptional regulation of the interferongamma promoter by glucocorticoids and dominant negative mutants of cJun. J Biol Chem, 1995. 270(21): p. 12548-56.

192.

Ogbomo, H., et al., Histone deacetylase inhibitors suppress natural killer
cell cytolytic activity. FEBS Lett, 2007. 581(7): p. 1317-22.

193.

Zhou, J. and J.A. Cidlowski, The human glucocorticoid receptor: one
gene, multiple proteins and diverse responses. Steroids, 2005. 70(5-7): p.
407-17.

159

194.

Eddy, J.L., Krukowski, K., Witek Janusek, L., Mathews, H.L., Chronic
low level glucocorticoid and immune dysregulation: Epigenetic priming at
pro-inflammatory loci. Journal Of Immunology, 2012. In the process of
submission.

195.

Conway-Campbell, B.L., et al., The HSP90 molecular chaperone cycle
regulates cyclical transcriptional dynamics of the glucocorticoid receptor
and its coregulatory molecules CBP/p300 during ultradian ligand
treatment. Molecular Endocrinology, 2011. 25(6): p. 944-54.

196.

Stavreva, D.A., et al., Ultradian hormone stimulation induces
glucocorticoid receptor-mediated pulses of gene transcription. Nat Cell
Biol, 2009. 11(9): p. 1093-102.

197.

Lightman, S.L. and B.L. Conway-Campbell, The crucial role of pulsatile
activity of the HPA axis for continuous dynamic equilibration. Nat Rev
Neurosci, 2010. 11(10): p. 710-8.

198.

Curcio, C., et al., Nonredundant roles of antibody, cytokines, and perforin
in the eradication of established Her-2/neu carcinomas. J Clin Invest,
2003. 111(8): p. 1161-70.

199.

Diefenbach, A. and D.H. Raulet, The innate immune response to tumors
and its role in the induction of T-cell immunity. Immunol Rev, 2002. 188:
p. 9-21.

200.

Daniel, M., et al., Associations among education, cortisol rhythm, and
BMI in blue-collar women. Obesity (Silver Spring), 2006. 14(2): p. 32735.

201.

Eatough, E.M., et al., Hormonal reactivity to MRI scanning in
adolescents. Psychoneuroendocrinology, 2009. 34(8): p. 1242-6.

202.

Encio, I.J. and S.D. Detera-Wadleigh, The genomic structure of the human
glucocorticoid receptor. Journal of Biological Chemistry, 1991. 266(11):
p. 7182-8.

160

203.

Manenschijn, L., et al., Clinical features associated with glucocorticoid
receptor polymorphisms. An overview. Annals of the New York Academy
of Sciences, 2009. 1179: p. 179-98.

204.

van Rossum, E.F. and S.W. Lamberts, Polymorphisms in the
glucocorticoid receptor gene and their associations with metabolic
parameters and body composition. Recent Progress in Hormone Research,
2004. 59: p. 333-57.

205.

Blume, J., S.D. Douglas, and D.L. Evans, Immune suppression and
immune activation in depression. Brain, Behavior, and Immunity, 2011.
25(2): p. 221-9.

206.

Piva, S.J., et al., Assessment of Inflammatory and Oxidative Biomarkers in
Obesity and Their Associations with Body Mass Index. Inflammation,
2012.

207.

Dokmanovic, M. and P.A. Marks, Prospects: histone deacetylase
inhibitors. Journal of Cellular Biochemistry, 2005. 96(2): p. 293-304.

208.

Rasheed, W.K., R.W. Johnstone, and H.M. Prince, Histone deacetylase
inhibitors in cancer therapy. Expert Opin Investig Drugs, 2007. 16(5): p.
659-78.

209.

Kee, H.J., et al., Activation of histone deacetylase 2 by inducible heat
shock protein 70 in cardiac hypertrophy. Circulation Research, 2008.
103(11): p. 1259-69.

210.

Tsai, S.C. and E. Seto, Regulation of histone deacetylase 2 by protein
kinase CK2. Journal of Biological Chemistry, 2002. 277(35): p. 31826-33.

211.

Kim, H.R., et al., Inhibition of casein kinase 2 enhances the death ligandand natural kiler cell-induced hepatocellular carcinoma cell death.
Clinical and Experimental Immunology, 2008. 152(2): p. 336-44.

161

212.

Ahmed, K., D.A. Gerber, and C. Cochet, Joining the cell survival squad:
an emerging role for protein kinase CK2. Trends Cell Biol, 2002. 12(5): p.
226-30.

213.

Yoo, J.Y., et al., Nuclear hormone receptor corepressor promotes
esophageal cancer cell invasion by transcriptional repression of
interferon-gamma-inducible protein 10 in a casein kinase 2-dependent
manner. Molecular Biology of the Cell, 2012. 23(15): p. 2943-2954.

214.

Ryu, B.J., et al., Anti-androgen receptor activity of apoptotic CK2
inhibitor CX4945 in human prostate cancer LNCap cells. Bioorg Med
Chem Lett, 2012. 22(17): p. 5470-4.

215.

Felten, D.L., et al., Noradrenergic and peptidergic innervation of
lymphoid tissue. Journal of Immunology, 1985. 135(2 Suppl): p. 755s765s.

216.

Fitzgerald, P.J., Is norepinephrine an etiological factor in some types of
cancer? International Journal of Cancer, 2009. 124(2): p. 257-63.

217.

Logan, R.W., A. Arjona, and D.K. Sarkar, Role of sympathetic nervous
system in the entrainment of circadian natural-killer cell function. Brain,
Behavior, and Immunity, 2011. 25(1): p. 101-9.

218.

Sanders, V.M., The beta2-adrenergic receptor on T and B lymphocytes:
do we understand it yet? Brain, Behavior, and Immunity, 2012. 26(2): p.
195-200.

219.

Benschop, R.J., et al., Beta 2-adrenergic stimulation causes detachment of
natural killer cells from cultured endothelium. European Journal of
Immunology, 1993. 23(12): p. 3242-7.

220.

Benschop, R.J., et al., Psychobiological factors related to human natural
killer cell activity and hormonal modulation of NK cells in vitro. Life
Sciences, 1993. 52(23): p. 1825-34.

162

221.

Watanabe, M., et al., Role of alpha-adrenergic stimulus in stress-induced
modulation of body temperature, blood glucose and innate immunity.
Immunology Letters, 2008. 115(1): p. 43-9.

VITA
Karen Krukowski was born in Houston, TX on November 10, 1983 to Ron and
Bobbie Krukowski.

She received a Bachelor of Arts in Microbiology from Miami

University of Ohio in May of 2006.
In August of 2006, Karen joined the Department of Microbiology and
Immunology at Loyola University Medical Center (Maywood, IL). Shortly thereafter,
she joined the laboratory of Dr. Herb Mathews and Dr. Linda Janusek, where she studied
mechanisms of immune dysregulation in individuals experiencing psychosocial distress,
focusing specifically on histone modifications associated with Natural Killer cell activity.
Karen’s concentration has been in psycho-neuroimmunology thus far, and hopes to
continue her post-doctoral work in this field or a related field. She is interested in
continuing human research, but would also like to pursue experimental models as well.

163

164

